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SUMMARY 
The eradication of glioblastoma multiforme (GBM) (WHO grade 4) remains a 
tremendous clinical challenge in human oncology. Indeed, this tumor accounts 
for the most common, aggressive and lethal primary brain cancer in adults, 
exhibiting a dismal prognosis, despite extensive surgical resection and adjuvant 
radio- and chemo-therapy. The finding that GBM contains functional subsets of 
cells with stem-like properties named glioblastoma stem cells (GSCs) has 
opened up novel opportunities and promises for the development of new 
therapies for this devastating cancer. GSCs are self-renewing, multipotent cells, 
with the capacity to establish and maintain glioma tumors at the clonal level, 
leading to the hypothesis that they are tumor-initiating cells. Moreover, these 
rare subpopulations of cells possess an elevated proliferative potential, and 
intrinsic resistance to therapy, being thus considered a key determinant driving 
tumor growth, and relapse after resection and therapy. In serum free culture 
conditions, GSCs form neurospheres. free-floating cell aggregates with a 
spheroid morphology. These neurospheres preserve many of the important 
characteristics of the parent tumor, as cell heterogeneity and the ability to drive 
the parent tumor’s cell invasiveness, when transplanted in murine brain. In 
addition, GSCs possess the capacities to give rise to a heterogeneous population 
of cells such as endothelial cells (glioblastoma endothelial cells, GECs) which 
may directly participate in the vascularization, a critical step in tumors, 
particularly in malignant GBM, one of the most vascularized/angiogenic tumor 
described. Moreover, it has been observed that microvasculature structures are 
the regions responsible for the localization and the maintenance of GSCs.  
Different molecules, including lipid mediators appear to play a key role in the 
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GBM microenvironment. Among lipid mediators involved in GSC properties, 
ceramide (Cer) and sphingosine-1-phosphate (S1P) has recently emerged as key 
signals, able to control growth, invasion, and therapy resistance in various 
human cancers, including GBMs. Of relevance, the presence of S1P in both 
glioma cell lines and human gliomas is critical for tumor cell proliferation and 
survival, a down-regulation of sphingosine kinase 1 (SK1) suppressed growth of 
human GBM cells and xenografts, and a higher expression of S1P receptor 1 
(S1PR1) in GBM has been correlated with poor prognosis. However, little is 
known on the role of Cer and S1P in GSCs. Recent studies reported that S1P 
acts as an invasive signal in GSCs, and that the inhibition of SKs, or the 
administration of a S1PR antagonist, results in GSC death. Very recently it was 
reported that GSCs derived from U87GBM cells, and those isolated from a 
human GBM specimen can release S1P extracellularly, and that S1P acts as a 
first messenger to enhance GSC chemoresistance to Temozolomide. 
In GSC invasiveness and chemoresistance very little is known about autocrine 
machinery controlling GSC proliferation and particularly on the significance of 
S1P in these events. In order to expand previous investigation on S1P and to 
better understand its role on GSC activity and chemoresistance in this project I 
focused on the pivotal role of S1P on GSC stemness properties.  
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INTRODUCTION 
1. Tumor of the Central Nervous System  
Different benign and malignant types of tumors, have been identified in the 
central nervous system (CNS). The prognoses for these tumors are related to 
several factors, such as the age of the patient, the location, the histology, the 
genetic, and the microenvironment of the tumor. In adults, about half of all CNS 
tumors are malignant, whereas in paediatric patients, more than 75%. 
Neurosurgeons can offer curative resections or at least provide significant relief 
from mass effect for benign CNS tumors that require treatments, unfortunately, 
effective treatments for most malignant CNS tumors still lack. Nevertheless, the 
past decade has witnessed an explosion in the understanding of the early 
molecular events in malignant CNS tumors, and new clinical trials has been 
developed to target these molecular events (Adamson, Rasheed et al. 2010). 
New evidence proposes that the growth of different types of cancer may be due 
to a subset of cancer cells which are responsible for resistance to therapy (Jordan 
CT, et al. 2006), and that have a significant expansion capacity to generate new 
tumors in relation to the neoplastic microenvironment (Reya T, et al. 2001). 
Moreover, within a solid tumor, in the bulk of cancer cells there are progeny of 
cancer stem cells, which can form new tumors and might represent a mix of 
partially differentiated cancer progenitor-like cells with limited proliferative 
capacity and terminally differentiated cancer cells, as cell with self-renewal 
capacity and transdifferentiating potential (Figure 1). 
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FIGURE 1: Different models of tumor formation and therapeutic targeting. 
Several healthy CNS cells can be potentially transformed in tumor initiating-
cells (TICs) and drive the tumor growth by genetic and/or epigenetic 
modifications, probably due to the single cell biology and/or “neoplastic 
microenvironment”. Various models are proposed on how these transformed 
cells can propagate and generate the tumor mass. No single model needs to 
apply to all tumor types, different models may apply to different tumor types or 
stages of malignant progression. (Adapted from Hadjipanayis & Van Meir, 
2009). 
 
Gliomas, so called because they arise from glial cells, are the most common 
primary brain tumours and an important cause of mental impairment and death 
(Wen PY & Kesari S, 2008). Glioma present some particular features that 
differentiate them from all the other CNS tumours. First, the distinction between 
benign and malignant lesions is less apparent than in other locations. Some glial 
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tumours with benign histological features, such as low mitotic index, cell 
uniformity and slow growth, can infiltrate entire regions of the brain, showing a 
clinically malignant behaviour. In addition, the anatomical location of the 
tumour can have fatal consequences regardless of histological features, for 
instance brain compression caused by an expanding tumour, resulting in severe 
neurological impairment.  
The World Health Organization (WHO), has provided numerous grading 
systems to differentiate gliomas. The most common is grading system that 
distinguishes four different grades of gliomas based on the pathologic evaluation 
of the tumor. Rendering to this grading system, tumours are classified  from I: 
least advanced disease with best prognosis, to IV: most advanced disease with 
worst prognosis.  
Moreover gliomas are classified as: i) Low-grade gliomas (LGGs), WHO grade 
II, are well-differentiated (not anaplastic); these are not benign but still indicate a 
better prognosis for the patient; ii) High-grade gliomas (HGGs), WHO grade III-
IV, gliomas are undifferentiated or anaplastic; these are malignant and carry a 
worse prognosis (Louis, Ohgaki et al. 2007). Grade I tumors are biologically 
benign and can be cured if surgically resected. Grade II tumors, as 
oligodendrogliomas are LGG that may follow long clinical courses, but early 
diffuse, and infiltration of the surrounding brain renders them incurable by 
surgery. Grade III tumors, as anaplastic oligodendrogliomas or astrocytomas, 
exhibit increased anaplasia and proliferation over grade II tumours and are more 
rapidly fatal. Grade IV tumours, as anaplastic astrocytoma and glioblastoma 
(GBM), exhibit more advanced features of malignancy, including vascular 
proliferation and necrosis, and as they are recalcitrant to radio- and chemo-
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therapy, they are generally lethal within 15 month. Furthermore, even the most 
malignant, GBM rarely metastasize outside of the CNS (Buckner JC, et al, 
2007). 
 
2. Glioblastoma Multiforme 
Glioblastoma multiforme (GBM) is the most common and aggressive human 
primary intracranial. It is the most common among gliomas with 54.7%, 
representing 15.7% of all CNS tumors, and 45.6% of malignant (WHO grade III 
and IV). The GBM is by only about 1% of adult malignancies, has an incidence 
of 3.19 per 100,000 and a different distribution in both sexes with a male/female 
ratio of 1.6/1. Predominantly it affects patients between 65 and 85 years, with a 
mean age at diagnosis of 64 years (Dolecek TA, et al., 2012). In most cases, 
GBM is a tumor of adult age, as in the group under 14 years is 0.2%, with an 
incidence rate of 0.14. The age of the tumor onset appears to be an important 
prognostic factor: several studies have shown a significant association between 
age and poor prognosis. Sex, however, seems to have no meaning in terms of 
outcomes (Walid MS.2008). 
 The GBM is burdened with one of the worst survival rates of all cancers in 
men, with a median that settles currently 14.6 months (Stupp et al., 2005). 
Survival rates relative, by age, are shown in Table 1. 
Histologically GBM is characterized by high cellularity and mitotic activity, 
vascular proliferation and necrosis. Because the cells of this cancer vary in size 
and shape (ie are pleomorphic), the term multiforme has been previously 
proposed. The GBM is characterized by uncontrolled proliferation, diffuse 
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infiltration of adjacent tissues, massive angiogenesis, high genomic instability, 
and apoptosis resistance to chemo-radiotherapy, features that are useful 
prognostic factors for overall survival. 
GBMs contain a subset of cells with characteristics of stem cell, called 
glioblastoma stem cells (GSCs) (Ignatova et al., 2002; Singh et al., 2004). The 
GSCs are self-renewing, multipotent, with the ability to establish and maintain 
the glial tumors and are therefore defined tumor-initiating cells (Bao et al., 2006; 
Lathia et al., 2011). In addition, they possess a high proliferative potential and 
intrinsic resistance to therapy, and may be considered as the determinant of 
tumor growth and the occurrence of relapses (Hadjipanayis and Van Meir, 
2009). 
GBMs can be divided into primary GBM (GBM or de novo) and secondary 
GBM (Rich & Bigner, 2004). Primary tumors comprise approximately 90% of 
GBM cases and are diagnosed without clinical or histological evidence of a 
previous low-grade neoplasia. They grow very quickly in older patients between 
60 and 70 years and are characterized by a brief medical history (two-thirds of 
patients, less than 3 months). The secondary GBMs represent the minority of 
cases (<10%), derived from a low-grade tumor that undergoes a process of 
progression to high grade tumor. The median time to progression from a LGG to 
GBM is 5.3 years, from anaplastic astrocytoma to GBM is 1.4 years. The 
secondary GBMs typically occur in younger adult subjects with a mean age at 
diagnosis of 45 years and the time of progression from low to high grade ranges 
from months to decades (Ohgaki & Kleihues., 2007; 2009). 
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An additional analysis using a robust gene expression-based molecular 
classification obtained on 200 primary GBMs has recognized four distinctive 
GBM subtypes: i) Proneural, ii) Neural, iii) Classical, and iv) Mesenchymal. 
Aberrations and gene expression of epidermal growth factor receptor (EGFR), 
neurofilament 1 (NF1), and platelet derived growth factor receptor alpha 
(PDGFRA)/isocitrate dehydrogenase 1 (IDH1) each define Classical, 
Mesenchymal, and Proneural phenotype respectively. Significant similarities, 
but not an entirely overlap, were found between the mesenchymal and proneural 
phenotype. An association was observed between the Proneural subtype and age 
and a trend towards longer survival. Furthermore, the data suggested that 
Proneural samples did not have a survival advantage from the aggressive 
treatment protocols introduced. Importantly, an evident treatment effect was 
observed in the Classical and Mesenchymal subtypes (Verhaak et al., 2010).  
 
TABLE 1. Survival rates related to age for GBM patients. 
Age range 1 year 2 years 5 years 10 years 
0-19 56.0 32.6 18.2 12.6 
20-44 67.2 36.8 17.6 10.0 
45-54 54.1 22.2 6.5 3.1 
55-64 42.3 15.1 4.1 1.5 
65-74 25.3 8.3 2.0 0.8 
75+ 10.6 3.1 0.9 - 
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2.1 Glioblastoma molecular markers 
The characterization of malignant tumors, often takes place through molecular 
analysis and detection of cancer biomarkers. In oncology, they are two classes: 
prognostic and predictive. The firsts indicate the possible outcome of the 
disease, independently of the treatment received; conversely, the predictive 
inform about the expected outcome after application of treatment protocols. 
Therefore, the predictive markers help in choosing between two or more 
treatment options and are important for personalized therapy (targeted therapy). 
Currently the widely used molecular markers to characterized GBM, evaluated 
in the clinical routine of brain tumors are the following: mutations of isocitrate 
dehydrogenase 1 and 2 (IDH1/2) gene, the methylation status of promoter of the 
MGMT gene, and the co-deletion of chromosomes 1p and 19q, 
2.1.1 IDH mutations  
Among molecular markers, IDH1 and IDH2 genotype are considered a valuable 
diagnostic and prognostic marker, since specific genetic mutations of these 
genes are able to affect the epigenetic profile of GBM. IDH1 and IDH2 are 
isoenzymes that convert isocitrate to α-ketoglutarate (α-KG) outside and inside 
the Krebs cycle, generating reduced NADPH from NADP
+
. IDH1 functions in 
the cytosol and peroxisomes, while IDH2 in the mitochondria. Although both 
IDH1 and IDH2 mutations are described in grade II and III gliomas and in 
secondary GBM, IDH1 appears mostly involved in GBM compared to IDH2. 
Considering the histotype, IDH1 mutations are found in 50-80% of 
astrocytomas, oligodendrogliomas and oligoastrocytomas, while they are very 
rare in primary GBMs, encountered in roughly 3%, overall (vonDeimling A, et 
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al., 2011). Interestingly, in diffuse gliomas IDH1 mutations are strongly 
associated with TP53 mutations, considered driver mutations, suggesting that 
also IDH1 mutations may represent an early event in gliomagenesis (Ogura R, et 
al., 2015). Nearly 100% of IDH1 mutations are substitutions at codon 132 
(Ogura R, et al., 2015). Initially, it was postulated that mutations in IDHs could 
abrogate the function of the encoded proteins, leading to a reduced synthesis of 
the α-KG metabolite. Striking new pieces of evidence have recently shown that 
the mutations compromise the affinity of the enzyme for the substrate and the 
formation of the product, resulting in increased levels of hypoxic inducible 
factor 1 α (HIF-1α), which facilitates tumor growth (Bolduc et al., 1995; Yan et 
al., 2009). 
2.1.2 MGMT methylation  
DNA methylation is an epigenetic modification consisting in adding a methyl 
group to cytosine or guanine nucleotides. Cytosine and guanine separated by a 
phosphate group are defined CpG islands, and are localized in the promoter 
region of about half of all human genes (Suzuki et al., 2009). DNA methylation 
at the hands of the family of methyltransferase enzymes, primarily occur in the 
CpG island and is associated with inactivation of transcription. 
The MGMT gene located on chromosome 10q26 encoding for an enzyme 
involved in DNA repair, which removes alkyl groups from guanine (Pegg, 
2000). The action of MGMT protects normal cells from carcinogens, but also 
repairs by lethal damage induced by alkylating chemotherapy, such as 
Temozolomide (TMZ). Methylation of the MGMT promoter is found in 35-45% 
of high-grade gliomas (HHG) and in 80% of low grade glioma (LGG) (Hegi et 
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al., 2005). Many clinical studies have shown that MGMT methylation is an 
independent prognostic factor associated with increased disease-free survival 
and overall survival of HHG, but not predictive of the sensitivity of the tumor to 
chemotherapy with TMZ (Gilbert et al., 2013). However, this is true for HGG 
patients whit tumor with IDH1 wild-type, where MGMT methylation is a 
predictive marker (Wick et al., 2013). 
2.1.3 Loss of heterozygosity (LOH)  
The most frequent genetic alteration in primary GBMs (up to 80%) is the loss of 
heterozygosity (loss of heterozygosity, LOH) of chromosome 10, often due to 
the loss of the allele (Ohgaki et al., 2004). LOH of chromosome 10 is also found 
up to 70% of secondary GBM, but in this case is generally partial. The 
chromosome 10 contains Phosphatase and tensin homolog (PTEN) and other 
tumor suppressor genes, which are therefore implicated in the pathogenesis of 
the tumor (Ichimura et al., 1998). 
Also LOH for 13q and 22q are seen in primary GBM (12% and 41%) and 
secondary (38% and 82%) (Nakamura et al., 2005), with involvement of the loci 
of pRb and of the tissue inhibitors of metalloproteinases, TIMPs. 
The LOH on chromosomes 1p and 19q is the most common abnormality found 
in oligodendrogliomas (Ohgaki et al., 2004), and the co-deletion is associated 
with increased chemosensitivity (Jenkin et al., 2006). Although LOH 1p is rare 
in primary GBMs (12%) and secondary (15%), it is associated with a higher 
survival. 19q LOH is more frequent in secondary GBM (54%), but rare in 
primary (6%) (Nakamura et al., 2000; Homma et al., 2006). 
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2.2 Glioblastoma treatment 
Glioblastoma tumors is one of the most aggressive and difficult to treat. It grows 
very quickly showing high resistance to apoptosis, after radio- and 
chemotherapy. Moreover, the spread of drugs in the intracranial compartment is 
complicated by the presence of the blood-brain barrier (BBB). The standard 
treatment of malignant gliomas involves surgical resection, when possible, 
radiation therapy and chemotherapy (Stupp et al., 2008). However, the prognosis 
for GBM is poor, and the survival rate at 2 years is less than 15% (Wen et al., 
2008; Rich et al., 2004). 
Due to their infiltrative nature, malignant gliomas cannot be completely removed 
by surgery, but resection must be maximal, as far as possible. Cytoreductive 
surgical treatment (debulking) reduces symptoms caused by mass effect and 
provides the fabric needed to histological diagnosis and molecular studies. 
Advanced techniques such as image-guided neuronavigation resonance imaging, 
magnetic resonance imaging (MRI), and intraoperative functional mapping or 
intraoperative fluorescence-guided surgery, have improved the safety of surgery 
and increased the extent of resection that can be obtained (Asthagiri et al., 2007; 
Stummer et al., 2006). 
Historically, radiation therapy (RT) has been the pillar of medical treatment of 
malignant gliomas (Walker et al., 1978). The addition of radiation therapy to 
surgery increased survival of patients with glioblastoma from 3-4 months to 7-12 
months. It has been shown that doses less than 45 Gy determined a 13 weeks 
median survival compared to 42 weeks with a dose 60 Gy (Barker et al., 1996). 
Therefore, nowadays, standard treatment involves the administration total of 60 
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Gy in 30-35 fractions of 1.8-2.0 Gy, 5 days a week. The response of GBM 
radiotherapy is different: in many cases it can induce a remission phase with 
stability or regression of the neurological symptoms and decrease the size of the 
mass of the absorbing contrast even if the tumor typically can occur within 1 
year, with neurological decline and expansion of the region absorbing contrast 
imaging. 
The addition of chemotherapeutic agents was then shown to increase the 
effectiveness of RT, albeit with a modest increase in survival (6-10% on the 
survival rate at 1 year) (Done et al., 1993; Stewart , 2002). Despite the optimal 
regimen of chemotherapy (CHT) was not yet completely defined, several studies 
showed that more than 25% of patients received a significant benefit in terms of 
survival, from adjuvant CHT. 
In recent years, Stupp et al, reporting the results of a randomized trial, reported 
that the combination of RT and TMZ, an oral alkylating agent with good 
penetration of the BBB, showed an increase in median survival compared to RT 
alone (14.6 months vs. 12.1 months) (Stupp et al., 2005). The survival rate at 2 
years among patients receiving RT and TMZ is significantly higher than that of 
patients with RT alone (26.5% vs 10.4%), establishing RT with concomitant 
TMZ, the better combination for newly diagnosed GBMs (Table 2). 
The recurrence in glioblastomas is however very frequent. The median time to 
recurrence of the disease after standard therapy was 6.9 months (Stupp et al., 
2005). It strictly depends on the nature of the infiltrative tumor, which does not 
allow the complete elimination of malignant cells, despite the gross-total 
resection. Up to 90% of recurrences occur within 2.3 cm from the primary 
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tumor, and only 5% of patients have multiple lesions. These pieces of evidence 
support the thesis that recurrences originate from cancer cells that have not been 
removed as result of previous treatments (Choucair et al., 1986; Gaspar et al., 
1992) and that have been sensitized and more resistan by RT and CHT therapies.  
Nowadays, GBM therapy considers surgery, chemotherapy and biological and 
experimental therapies (Wernicke et al., 2011). RT for recurrence is 
controversial, although some studies have suggested benefits with stereotactic 
RT or fractionated stereotactic re-radiation. The median survival after resection 
of the recurrence is 3.5 months to 1 year (Nieder, et al., 2000). 
 
TABLE 2: Gold Standard Treatment for Glioblastoma  
Treatment  
Preoperative 
 
High-dose corticosteroids, dexamethasone 8-
16 mg / day. Any AED therapy (lamotrigine, 
levetiracetam, pregabalin). 
Surgery 
 
Resection ceiling. 
Radiotherapy 
(RT) 
Conformational fractionated in 30-35 daily 
doses of 1.8-2 Gy, 5 days a week, for a total 
of 60 Gy. 
 
Chemotherapy 
(CHT) 
 
Concomitant TMZ, 75 mg / m2 / day po on 
days 1-42, typically 1-1,5h before RT. 
TMZ adjuvant at high doses, 150-200 mg / 
m
2
 / day po on days 1-5 every 28 days for 6 
cycles. 
 
 
 
22 
 
2.2.1 Antineoplastic agents.  
 Temozolomide (TMZ) is an oral alkylating agent used for newly 
diagnosed GBM. TMZ administration and adjuvant concomitant radiation 
therapy is associated with a significant increase in disease-free survival 
(progression-free survival, PFS) compared with RT alone (6.9 vs. 5 months), 
overall survival (overall survival, OS) (14.6 vs 12.1 months), and the probability 
of survival at 2 years (26% vs 10%). MGMT is an enzyme involved in DNA 
repair, which contributes to TMZ resistance. The methylation of the promoter of 
MGMT gene, found in about 45% of GBMs, determines an epigenetic silencing 
of the gene and reduces the ability of GBM cells to repair the damage, increasing 
susceptibility to TMZ. After TMZ treatment, patients with and without 
methylation have a median survival of 21.7 vs. 12.7 months, and a 2-year 
survival rate of 46% against 13.8%, respectively. 
 The biodegradable polymer impregnated with Carmustine (BCNU) 
 (Gliadel wafer), placed in the surgical cavity created after tumoural 
 resection, allows for delivery of the drug directly to the site of the brain 
 tumors. Carmustine showed a modest increase in survival (13.8 vs 11.6 
 months), although with increased risk of leakage of cerebrospinal fluid 
 and intracranial hypertension, edema and abnormal wound healing 
 process.  
 The Fotemustine is a nitrosourea characterized by high lipid solubility 
 and low molecular weight that favour the passage through the BBB. The 
 antitumor effect is related to the ability to alkylate DNA. It is indicated 
 mainly in recurrent GBM (Beauchesne, 2012).   
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 The anti-angiogenic agent Bevacizumab (Avastin) is a recombinant 
 monoclonal antibody directed against VEGF-A, causing reduction of 
 tumor vascularization, and inhibiting the tumor growth. Bevacizumab 
 was approved by the FDA in 2009 for GBM treatment. Administered in 
 combination with irinotecan (CPT-11), Bevacizumab, in recurrent 
 gliomas, improves disease-free survival at 6 months, from 21% in 
 patients treated with TMZ alone, to 48%. Some data suggest, moreover, 
 that the anti-angiogenic therapy improves the efficacy of RT. 
 Retrospective and prospective studies have shown that the anti-
 angiogenic therapy increases the PFS in HGGs. However, the efficacy of 
 bevacizumab in increasing overall survival, to date, is yet to be verified 
 (Norden et al., 2009). Indeed, numerous patients were resistant to 
 Bevacizumab treatment, probably due to the up-regulation of alternative 
 angiogenic factors following VEGF inhibition, such as PDGF/PDGFR-b, 
 FGF, SDF-1a, and angiopoietin-1 (Ang-1)/Tunica interna endothelial cell 
 kinase homolog (Tie-2), or increased pericytes mobilization, endothelial 
 cell survival factor secretion, and induction of aggressiveness of GSC 
 invasive phenotype with host blood-vessel appropriation and gliomatosis 
 (Reardon DA, et al., 2008). 
 Other promising areas of research include combination therapies of anti-
 VEGF inhibitors with vaccine strategies, immune checkpoint inhibitors, 
 and other treatment modalities, such as newer radiotherapy techniques. 
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2.3 Glioblastoma Cancer Stem Cells in tumor pathogenesis 
Within the GBM tumor mass are recognizable different cell subpopulations; 
among them cancer stem cells (CSCs) were identified as responsible for tumor 
birth, formation, proliferation, aggressiveness, recurrence, and resistance to 
therapy (Nduom EK, et al., 2012). These CSCs, named glioblastoma stem cells 
(GSCs), has been demonstrated to share some features with the already known 
somatic stem cells present in different human tissues (including the brain tissue, 
where normally are presented neural stem cells, NSCs), including self-renewal 
(by symmetric and asymmetric division) and differentiation capacity, albeit 
aberrant. Like the common stem cells, GSCs express certain surface markers, 
such as membrane antigen prominina-1 (CD133). CD133 is a transmembrane 
protein, used to mark “side population”. Initial studies delineated clear 
differences between CD133 positive (+) and negative (-) glioma cells, including 
a dramatic difference in tumor-forming capacity in xenografts (Singh SK et al., 
2003), but further studies have shown that also CD133(-) stem-like cells may 
also be tumorigenic (Beier D, et al., 2007; Sakariassen PO, et al., 2006). More 
recent studies suggest a high level of plasticity within this stem-like cancer cell 
population, as CD133(-) cell populations can produce CD133(+) cells after 
generating tumors in immunodeficient nude mice (Wang J, et al., 2008). These 
studies suggest that CD133 is not necessarily expressed in the GSCs in gliomas 
and there should be more general and sensitive makers for CSCs in gliomas. 
Previous studies demonstrated that GSCs expressed the main brain cancer stem 
cell markers: the cytoskeleton protein nestin (Zhang M, et al., 2008). Nestin is an 
intermediate filament protein expressed in the stem/progenitor proliferating cells 
during the CNS developmental stages and its expression is down-regulated in 
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differentiated cells. It may be involved in the organization of the cytoskeleton, 
cell signalling and metabolism, organogenesis, and represents the proliferation, 
migration and multi-differentiated characteristics of multi-lineage progenitor 
cells (Hadjipanayis CG & Van Meir EG, 2009). Moreover in previous study He 
and colleagues, demonstrated that the expression level of CD90, in GBM 
neurospheres was significantly increased than that in three traditional GSC 
adherent lines (He J et al., 2010). More recently, the same authors reported that 
CD90(+) cells were clustered around the tumor vasculatures in HGG tissues, 
suggesting a potential prognostic role for CD90 in HGG and a marker for  CSCs 
within gliomas. Indeed, CD90(+) cells reside within endothelial niche and may 
also play a critical role in the generation of tumor vasculatures via differentiation 
into endothelial cells (He J, et al., 2012). It is possible to speculate that CD90(+) 
cells play a pivotal role in GBM angiogenesis, as seems that thy do not are 
responsible for tumor stemness (Woo SR, et al., 2015). The majority of CD90(+) 
cells in human GBM tissues expressed CD31, CD34 and von Willebrand factor, 
suggesting that they were endothelial cells (Inoue A, et al., 2015).  
The neovascularization significantly correlated with enhanced tumour 
aggressiveness, degree of tumour malignancy, and poor clinical prognosis. 
Active angiogenesis, in fact, acting as a crucial event in providing oxygen and 
nutrients to the tumour mass as well as facilitating tumor progression, in 
particular in GBM, the most malignant and hypervascularized brain tumor. 
Indeed, it has been reported an activaction of multiple pro-angiogenic signalling 
pathways. Evidence establish that a pivotal role for its recaclcitrant behaviour 
could be assigned to the reciprocal crosstalk between GSCs and their 
microenvironment where endothelial cells are the principal actors. The 
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angiogenic process is promoted by Vascular Endothelial Growth Factor (VEGF) 
secretion from tumor vascular niche (Figure 2). Indeed, the GBM 
neovascularization significantly correlated with enhanced tumour 
aggressiveness, degree of tumour malignancy, and poor clinical prognosis (Li Z, 
et al., 2009). 
However, these molecules are not GSCs universal enriched markers. In fact, it 
has been observed that the stage-specific embryonic antigen CD15, or stage-
specific embryonic antigen 1 (SSEA-1), originally identified as a surface marker 
of mouse embryonic stem cells, has been recently used as an alternative marker 
to enrich GSCs. CD15(+) cells are often also CD133(+) and, within the tumour, 
are able to self-renewal, show a multilineage differentiation potential and are 
highly tumorigenic in vivo (Son MJ, et al., 2009). Recent research of Kenney-
Herbert and colleagues, focused on pathogenic role for CD15 in GBM, 
demonstrated that CD15 could not isolate a phenotypically or genetically distinct 
population of CSCs in GBM. Moreover, isolated CD15(+) and (-) cells were 
able to generate mixed populations of GSCs in vitro without any significant 
differences in term of proliferation, aggressiveness, and xenograft tumor 
formation (Kenney-Herbert E, et al., 2015).  
As a general consideration, these papers show that a single marker cannot be 
considered essential to target GSCs, in agreement with the notions that CSCs are 
not represented by one particular phenotype and different glioma stem cell 
populations (based on the expression of various markers) are present in this 
heterogeneous tumor. Thus, a variety of markers has to be used to better identify 
stem cells in all tumor cases. 
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FIGURE 2: Tumor microenvironment. Regulated by oncogene activation or 
microenvironment conditions such as hypoxia, GSCs that reside in the 
perivascular niche are consistently affected by signals from tumor 
microenvironment, such as hypoxia, and neighboring cells (i.e. endothelial 
cells). In this scenario GSCs are able to secrete growth factors including pro-
angiogenic factors such as VEGF that strongly stimulate angiogenesis. On the 
other hand, the cells of the tumor vascular compartment provide optimum 
conditions for the growth of GSCs. 
 
 
3. Sphingolipids  
In the last few years it has shown the crucial role of important metabolites, 
present at the level of the tumor cells and microenvironment, in determining 
some important characteristics such as the degree of malignancy, invasiveness, 
resistance to apoptosis. In this scenario, sphingolipids have emerged as crucial 
players. The term sphingolipids include a family of amphipathic lipids that 
possess functional and structural properties characterized by a hydrophilic (or 
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polar head) and a hydrophobic (or tail) portion. The structural element common 
to all sphingolipids is represented by N-acylated sphingosine, termed ceramide 
(Cer). They are ubiquitous as components of cell membranes (both in the plasma 
membrane, as in the intracellular organelles membranes), where present a 
polarized or asymmetric distribution and regulate the membrane fluidity and 
structure. Additionally, different stimuli applied to cells (such as UV radiation, 
chemotherapy, growth factors, etc.) generate metabolic reactions that lead to the 
production of different intermediate of sphingolipid metabolism, and particularly 
sphingosine (Sph), S1P, Cer, glucosyl-ceramide (GlcCer) and ceramide-1-
phosphate (Cer1P). These molecules act as bioactive ones, and are involved, as 
intra- or extra-cellular messengers, in the regulation of crucial processes as cell 
growth, death, migration and senescence (Mignard V, et al., 2014). Although the 
sphingolipid family exhibits multiple diversity for structure and function, they 
show common biosynthetic and catabolic pathways. The center of sphingolipids 
metabolism is Cer that can be produced in at least three distinct ways. First, it 
can be originated from the de novo pathway, second, through the hydrolysis of 
complex sphingolipids (sphingomyelin and glycoshingolipids), and finally, 
through the recycling of fromsphingosine, derived complex sphingolipids 
catabolism (Adan-Gokbulut et al., 2013). 
3.1  Ceramide 
The backbone of the sphingolipids is the ceramide (Cer), a lipophilic molecule 
whose training is the first step in sphingolipid biosynthesis (Figure 3). 
Cer is present in small amounts within cell membranes, as it functions primarily 
as an intermediate of complex sphingolipid metabolism and acts as a cell 
signalling mediator (Futerman AH & Hannun YA, 2004). 
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Cer is heterogeneous in its structure, as fatty acids with different acyl chain 
lengths, double bonds and hydroxylations can be present in the molecule 
(Merrill AH Jr, et al., 2009). Notably, this heterogeneity depends not only on the 
availability of different fatty acyl precursors, but mainly on the action of specific 
enzymes controlling the production of specific ceramide species (Park JW, et al., 
2013). 
Cer can be synthesized de novo, from the condensation of L-serine and 
palmitoyl-CoA, or by a route of recycling of Sphingosine (Sph), produced by the 
catabolism of sphingolipids. These processes occur all at the level of the 
endoplasmic reticulum (ER); Cer is then translocated to the level of the Golgi 
apparatus for the synthesis of glucosylceramide (GlcCer), ceramide 1-phosphate 
(Cer1P) and sphingomyelin (SM) (sphingomyelin knows also another synthetic 
route to the outside of the apparatus Golgi). 
Recent studies have focused on the investigation of trafficking of ceramide 
within the cell; in particular, as mentioned above, it has identified a protein, 
called CERT, which mediates the transport of Cer, ATP-dependent, from the 
endoplasmic reticulum to the Golgi mechanism with non-vesicular mechanism 
(Giussani P et al., 2008). A modulation of the Cer levels in ER-Golgi 
compartment could be crucial for the regulation of its functions; in fact, it has 
been shown that the de novo Cer generation, its removal through the synthesis of 
SM and the inhibition of its transport to the site of SM synthesis are responsible 
for variation of Cer involved in the control of cell proliferation and in apoptosis 
of glioma cells (Viani P. et al., 2003).  
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FIGURE 3: Schematic representation of ceramide and of the main related 
sphingolipids metabolism. SPT, serine-palmitoyl transferase; CerS, ceramide 
synthase; DES, dihydroceramide desaturase; GCS, glucosylceramidesynthase; 
GDase, glucosylceramidase; S1PP, S1P phosphatase; SK, sphingosine kinase; 
PC, phosphatidylcholine; DAG, diacylglycerol; SMase, spingomyelinase; SMS, 
sphingomyelin synthase; C1P, ceramide-1-phosphate; CerK, ceramide kinase 
 
Among several glioma cell lines, differences with regard to the fatty acyl chain 
distributions of Cer were detected using liquid chromatography tandem mass 
spectrometry (Sullards MC, et al., 2003), suggesting heterogeneity in ceramide 
subfamilies in different GBMs. Of interest, a specific reduction in C18 ceramide 
was recently shown in human gliomas as a function of their malignancy grade, 
and, notwithstanding their great heterogeneity, low levels of C18 ceramide were 
common to different GBMs (Abuhusain HJ, et al., 2013). In head and neck 
squamous cell carcinoma, C18 ceramide was found to be the only form of Cer 
whose levels were decreased, and its levels inversely correlated with metastasis 
(Karahatay S, et al., 2007), suggesting that reduced C18 ceramide levels may 
also contribute to GBM malignancy. 
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3.2 Sphingosine-1-phosphate  
Sphingosine-1-phospahte (S1P) is  an intermediate of sphingolipid metabolism 
and play an important role as bioactive molecules. S1P metabolism is finely 
regulated through the modulation of different enzymes responsible for its 
synthesis and degradation (Le Stunff H, et al., 2004). S1P is formed from 
sphingosine (Sph) and ATP in a reaction catalyzed by two isoenzymes, 
sphingosine kinase 1 (SK1) and sphingosine kinase 2 (SK2) (Liu H, et al., 2002). 
Among all the intermediate of sphingolipids metabolism, S1P is involved in 
various roles like intra- or extracellular messengers for growth, death, adhesion 
and cell migration. With the hypothesis to demonstrate the crucial role for 
sphingolipids in tumor process, in my research project I focused on the S1P 
onco-promoter ability to act as extracellular signal, favours proliferation, 
stemness, angiogenesis and chemoresistance properties in GSCs. 
S1P is a sphingolipid metabolite able to perform multiple tasks, and to act as 
powerful biomediator in various biological processes. S1P is a bioactive 
molecule that has antiapoptotic properties through antagonising Cer-mediated 
apoptosis by activating ERK and suppression of ceramide-induced JNK 
activation (Cuvillier, O.; et al., 1996). Moreover, previous works, performed in 
both cell cultures and animals, demonstrated that S1P can modulate pathological 
processes strictly related to cancer and inflammation, favouring cell survival, 
migration, and angiogenesis (Hannun YA, et al., 2008). S1P can exert its 
bioactive properties in the intracellular milieu, acting as a second messenger, and 
mainly in the extracellular milieu , where, after secretion from cells, can bind 
five specific cell surface receptors (S1P1-5) coupled to different G-proteins and 
32 
 
thereby activating several signal transduction pathways that control cell 
behaviour (Payne SG, et al., 2002) (Figure 4). 
 
 
FIGURE 4: Schematic representation of sphingosine-1-phosphate roles. The 
bioactive properties of S1P in GBM tumor miscroenvironement is shown. SKs, 
sphingosine kinase; S1PR, sphingosine-1-phosphate receptor.  
 
As mentioned above, S1P has emerged as an onco-promoter molecule. S1P is 
produced by the enzyme SphK, SK1 and SK2, these isoforms, together, 
differentially regulate cell fate, survival, migration, angiogenesis, and drug 
resistance, protecting cancer cells from chemotherapy-induced apoptosis, as 
shown on GBM cell lines and primary glioma CSCs (Riccitelli, E.; et al., 2013; 
Estrada-Bernal A, et al., 2006). It has been established that GBM cell lines and 
tissue specimens showed high expression for SK1 (Zhang  H, et al., 2012), 
which correlates in HGG patients with worse prognosis and poor patient 
survival. Furthermore, the pharmacological inhibition of SK1 and SK2, or their 
silencing, decreased the GBM cell  proliferation rate, preventing the entry into 
the cell cycle (Van Brocklyn JR, et al., 2009), and restores the sensitivity of 
GSCs to TMZ (Riccitelli E et al., 2013). 
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3.3 Sphingosine-1- phosphate aberrations in GBM 
To reinforce their malignancy and their capacity to survive and colonize, GBMs 
adapt diverse ‘crafty’ strategies and, among them, exhibit aberrations in 
sphingolipid metabolism and thus altered sphingolipid levels. A key point 
appears to reside in the down-regulation of ceramide levels. Indeed, ceramide 
levels are lower in human GBM tissue compared to normal surrounding brain 
tissue, and the decrease in ceramide in GBMs is directly related to histological 
grade and patient survival (Riboni L, et al., 2002). The decrease in total 
ceramides with increasing glioma grade was found parallel to an increase in S1P 
content, ceramide and S1P levels being on average twofold lower and nine fold 
higher, respectively in GBM tissues than in normal gray matter (Abuhusain HJ, 
et al., 2013). In addition, human GBM specimens and tumor cells have markedly 
lower levels of sphingomyelin than non-tumor cells and normal brain, 
respectively (Campanella R, 1992; Barceló-Coblijn G, et al., 2011), and a recent 
report showed that, besides low ceramide, decreased sphingomyelin levels are 
associated with the GBM tumorigenic transformation (Terés S, et al., 2012). 
Recent studied provided evidence about possible molecular explanations 
responsible for the aberrant levels of ceramide and S1P in GBMs. Indeed, acid 
ceramidase (A-ceramidase), which converts ceramide to sphingosine, was found 
to be significantly up-regulated in GBM specimens (Abuhusain HJ, et al., 2013). 
Moreover, Jensen et al. (Jensen SA, et al., 2014) showed that B-cell lymphoma 
2-like 13 (Bcl2L13), an atypical member of the Bcl-2 family overexpressed in 
GBM, acts as ceramide synthase (CerS) inhibitor. 
Interestingly, through its binding to, and inhibiting CerS2 and CerS6 activity, 
Bcl2L13 functions as an anti-apoptotic protein by protecting the mitochondrial 
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membrane integrity. With regard to the increased level of S1P, a likely 
explanation should reside in the high expression of both SphK1 and SphK2 in 
GBMs (Van Brocklyn JR, et al.,  2005; Li J, et al., 2008; Quint K, et al., 2014). 
In addition to SphK up-regulation, it was found that the S1P phosphatase 2 
(SPP2), a S1P specific phosphohydrolase localized to the endoplasmic reticulum 
(ER) (Ogawa C, et al., 2003), is significantly downregulated in GBM as 
compared to normal gray matter samples (Abuhusain HJ, et al., 2013). Of note, 
SPP1 expression has been shown to increase ceramide levels at the ER by the 
recycling of its product sphingosine (Le Stunff H, et al., 2007), suggesting that 
the loss of SPP2 expression in GBM not only increases S1P but also drives Cer 
levels down. Of relevance is also the finding that the chromosomal region 
containing the gene for S1P lyase is deleted in human GBMs (Steck PA, et al., 
1995), most likely favouring high levels of S1P in this cancer.  
Thus it emerged that GBM is equipped to down-regulate ceramide and up-
regulate S1P to drive a systematic shift in sphingolipid balance which may 
favour aggressiveness and protection from death. In agreement, using a 
mathematical model to construct how sphingolipid metabolism is altered in 
GBM cells compared to normal astrocytes, Mora et al. (Mora R, et al., 2010) 
observed that a key difference is the preferential channelling of complex 
sphingolipids into S1P synthesis in GBM cells, whereas in normal astrocytes, 
sphingosine formed in the lysosomes is mainly recycled into ceramide. S1P 
exerts multiple roles through its five specific receptors (S1P1–5) (Rosen H & 
Goetzl EJ 2005), and S1P1–3 and S1P5 receptors were found in human GBM 
specimens (Yoshida Y, et al., 2010;). In a recent study, Quint et al. (2014) 
reported that the mRNAs for all these receptors are up-regulated in human GBM 
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specimens compared to normal brain, with increasing order of magnitude from 
primary, up to recurrent and secondary GBMs (Quint K, et al., 2014). 
Growing evidence implicates a complex interplay between GSCs and their 
microenvironment in determining GSC properties and maintenance (Filatova A, 
et al., 2013). Very recent studies demonstrated that GSCs are equipped with an 
efficient molecular machinery that allows them to rapidly synthesize S1P from 
sphingosine, as well as to export the newly produced S1P in their 
microenvironment (Riccitelli E, et al., 2013; Marfia G, et al., 2014). GSCs 
appear to share with normal cells of the nervous system, such as neurons and 
astrocytes, and also human GBM cells the capability of releasing S1P in the 
extracellular milieu (Anelli V, et al., 2005; Anelli V, et al., 2010). Of relevance, 
the amount of extracellular S1P provided by GSCs was found to be markedly 
higher (about tenfold) than that by astrocytes and non-stem GBM cells 
(Riccitelli E, et al., 2013). It is worth noting that, among stem cells, the export of 
S1P seems specific to GSCs, as neural stem cells have been reported to be 
uncapable of this export (Kimura A, et al., 2007). Thus it appears that, different 
from neural stem cells, GSCs possess the unique ability to enrich their 
extracellular milieu with S1P, that in turn could act as a autocrine/paracrine 
signal favouring tumor progression. 
As mentioned before, GBM is one of the most highly vascularized tumor in man, 
and its blood vessels show enhanced endothelial cell proliferation, which is a 
key feature of their classification in the WHO grading system. The main trigger 
of angiogenesis processes in GBM is hypoxia, mainly localized in the center part 
of the tumor, and driven primarily by VEGF, induced by hypoxia inducible 
factors (HIFs).  
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Importantly, under hypoxia SphK1 up-regulates HIF-1 in GBM cells, by 
stabilizing HIF-1α through the Akt pathway and preventing its proteasomal 
degradation (Ader I, et al., 2008). It was also shown that HIF-2α up-regulation 
of SphK1 in GBM cells leads to enhancement of neovascularization (Anelli V, et 
al., 2008), and its product S1P acts as potent mediator of angiogenesis as VEGF 
(Liu Y, et al., 2000), most likely through its specific receptor S1P1. Moreover, 
S1P is a downstream target of different pro-angiogenic growth factors such as 
VEGF, EGF, PDGF, bFGF and pro-angiogenic cytokines such as interleukin 
(IL)-6 and IL-8 leading to a positive signaling loop (Shu X, et al., 2002).  
Interestingly, it was found that in GBM cells SphK1 down-regulation, but not 
that of SphK2, reduced extracellular S1P levels, which in turn decreased both 
migration and tube formation in co-cultured vascular endothelial cells (Anelli V, 
et al., 2010). In addition, VEGF down-regulation was unable to block the 
angiogenic switch triggered by GBM-derived S1P. In GBM cells S1P is able to 
initiate endothelial cell sprouting, which is representative of a multistep 
angiogenic process, and SphK1 plays an essential role in regulating paracrine 
angiogenesis, favouring the early sprouting response of endothelial cells by 
increasing both number and length of sprouts (Abuhusain HJ, et al., 2013). 
Notably this effect was induced by S1P released by GBM cells, and was not 
affected by VEGF (Abuhusain HJ, et al., 2013), suggesting that S1P signaling is 
required even when potent angiogenic factors such as VEGF are present. 
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AIM OF THE WORK 
Glioblastoma multiforme (GBM), the highest grade of gliomas (World Health 
Organization Grade IV), is the most aggressive and malignant human brain 
cancers, with a short prognosis (Siegel R, et al., 2012). Indeed, despite the 
introduction of aggressive and multi-modal therapy with neurosurgery, radiation, 
and chemotherapy, current treatment regimens have modest benefits, and 
recurrence of GBM is nearly universal. The overall median survival time of 
adult patients remains as short as 12–14 months (Serwer LP et al., 2012), only 
3–5 % of patients surviving more than 3 years, with a median survival of only 5–
7 months with optimal therapy (Krex D, et al., 2007). Increasing evidence 
suggests that a subpopulation of cells within the tumour, named Glioblastoma 
Stem Cells (GSCs), that possess transcriptional and epigenetic programs that 
endow them with stemness properties (Dick JE 2008), appears crucial in both the 
initiation and maintenance of this tumour, and might play a fundamental role in 
(i) its malignant growth, (ii) in recurrence and (iii) in resistance to chemo- and 
radiotherapies.  Although the mechanisms of GBM onset and progression remain 
unclear, recent advances in the understanding of the aberrations of signalling 
pathways associated with GBM have opened a new window in the 
comprehension of its aggressiveness (Charles NA, et al., 2011). Indeed, multiple 
oncogenic signalling aberrations are associated with GBM, and drive its 
aggressive behaviour. An increasing amount of evidence indicates that also 
alterations in sphingolipid signalling play important roles in GBM, participating 
in its progression and malignant properties. However, there are still several 
discrepancies as well as unanswered questions. Among them, little is known 
about the mechanisms underlying Cer and S1P dysregulation. It is also unclear 
38 
 
how the multiplicity of functional actions of S1P is utilized by GBM as signal 
enhancement for their microenvironment, and the possible molecular circuits 
that integrate sphingolipids with other cell-regulatory elements of GBM. 
Particularly it is still unclear if GSCs are able to produce and release their own 
S1P extracellularly, or if S1P secreted by other neighbour cells, is the 
responsible for the S1P mediated responses found in GSCs. Using GSC lines 
derived from human glioblastoma specimens with different proliferative index 
and stemness marker expression, we assessed the hypothesis that sphingosine-1-
phosphate (S1P) affects the proliferative and stemness properties of GSCs.  
On these premises, the aim of this PhD project was to investigate the ability of 
GSCs to produce and release S1P in the extracellular milieu, as strategy to 
escape pharmacological and radio-chemo-therapies. Moreover, we evaluated the 
possible involvement of S1P as an autocrine/paracrine factor modulating 
proliferation and stemness response in GSC,, favouring a  pro-stemness 
environment. Moreover, we evaluated the possible involvement of fingolimod 
(FTY720), a S1P receptor agonist, approved by the FDA for the treatment of the 
relapsing forms of multiple sclerosis (Kappos L, et al., 2010), in modulating the 
resistance to Temozolomide. The overall rationale of this research was that a 
deeper comprehension of the mechanism of S1P secretion and action in GBM 
microenvironment could improve our understanding of the GSC chemo-
resistance, representing a critical step to develop new GBM therapeutic 
compounds able to modulate S1P metabolism to curtail GBM progression.  
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MATERIALS METHODS 
4.1 Patients and study design 
This was an observational study performed on patients affected with grade IV 
gliomas who underwent neurosurgical procedures at the Neurosurgery Units of 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in the last 3 
years. Demographic and clinical data were retrospectively collected from 
patients’ files, starting from the date of diagnosis until death or the date of the 
last visit performed, whichever came first. Karnofski Performance Status (KPS) 
was assessed on the day before surgery. Written informed consent was obtained 
from patients or their caregivers before surgery. The study was approved by the 
Institutional Review Board of the hospital.  
 
4.2 Eligibility 
 Patients of both sexes with newly diagnosed malignant brain tumors who signed 
a written informed consent were eligible for this study. Inclusion criteria were: 
intraoperative histologically proven diagnosis of malignant brain tumor on 
review by two independent pathologists; 18-80 years of age; Karnofsky 
performance status >60; negative human immunodeficiency virus serology; no 
evidence of acute or chronic hepatitis on standard hepatitis C and B screening 
tests; no second malignancies. Exclusion criteria were: not proven diagnosis of 
malignant brain tumor by the biopsy during the operation of malignant brain 
tumor after surgical resection; concomitant life-threatening disease; presence of 
acute (including respiratory) infection; positive serology for human 
immunodeficiency virus, hepatitis B or C; history of other malignancies; and 
compliance with the study protocol.  
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4.3 Histopathological Analyses 
Histology was performed on specimens fixed in a 4% paraformaldehyde (PFA) 
solution (Sigma-Aldrich, Basel, Switzerland) in Dulbecco’s phosphate-buffered 
saline (D-PBS) (Euroclone, Milan, Italy) and subsequently embedded in 
paraffin, cut at 30 µm, and stained with haematoxylin-eosin. GBM samples were 
histologically confirmed and classified as grade IV GBMs, in accordance with 
WHO established guidelines (Louis et al., 2007). 
 
4.4 Immunohistochemistry 
The sections were deparaffinised and then dehydrated. In the next step, blocks 
were incubated in fresh citrate/HCl buffer solution for antigen recovery and, 
after 60 min incubation, were washed with D-PBS. Samples were then incubated 
with biotinylated monoclonal Ki-67/MIB1 antibody (1:100; Ventana, Tucson, 
AZ, USA) and rabbit anti-glial fibrillary acidic protein (GFAP; 1:200, 
Chemicon, Temecula, CA, USA). Then the slides were exposed to peroxidase-
labeled streptavidin followed by washing with D-PBS, and finally exposed to 
diaminobenzidine hydrochloride chromogen (BD Biosciences, San Jose, CA). 
Afterwards, they were covered with coverslips following dehumidification. 
Stained slides were observed by a pathologist using an Olympus BX41 
(Olympus, Tokyo, Japan) light microscope. 
One thousand tumor cells were counted in several areas of tissue where 
positively stained nuclei were evenly distributed. In those cases with uneven 
distribution of positive nuclei, the tumor cells were counted in the areas with 
highest density of positive nuclei by visual analysis (Ralte et al., 2001). The 
Ki67 labelling index was calculated as a percentage of labelled nuclei. 
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4.5 Loss of heterozygosity 1p and 19q 
Loss of heterozygosity (LOH) of chromosome arms 1p and 19q was assessed by 
short tandem repeats (STR) analysis using paired tumor specimens and PBLs. 
The LOH was investigated using the following STR markers: D1S468, D1S548, 
D1S2666, D1S1612, D19S918, D19S596, D19S206. A total of 100 ng of tumor 
and PBL DNA was amplified by PCR, with settings optimised individually for 
each primer pair. PCR products were then analysed by capillary gel 
electrophoresis on the GeneMapper ABI 3130XL (Applied Biosystems, Foster 
City, CA, USA). Criteria used to establish LOH were the same reported by 
Johnson et al. (Johnson MD1, et al., 2003). 
 
4.6 Detection of IDH1 and IDH2 mutations 
IDH1 codon 132 and IDH2 codon 172 mutations were screened by MassArray 
iPLEX platform (Agena Bioscience, Hamburg, Germany) based on matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometry. PCR and downstream reactions were performed according to the 
manufacturer’s instructions. PCR and Extended primers were designed manually 
to detect all possible nucleotide substitutions at these positions and specific oligo 
tag sequences were added to the 5’end of each PCR primer to optimize the PCR 
reaction. PCR multiplex amplification was conducted in 5μl reaction mixture 
containing 30 ng of tumor DNA, 100 nM each designed primers, 100 nM dNTP 
mix, PCR buffer, 25 mM MgCl2, and 5U Taq DNA polymerase (Agena 
Bioscience, Hamburg, Germany). The mixture was incubated as follows: 95 °C 
for 2 minutes, 45 cycles of 95 °C for 30 seconds, 56 °C for 30 seconds, and 72 
°C for 60 seconds and then a final extension step at 72 °C for 5 min. The 
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remaining unincorporated dNTPs were removed by the SAP treatment with 1.7 
U of Shrimp Alkaline Phosphatase (SAP): the plates were incubated at 37 °C for 
40 min and then at 85 °C for 5 min. Finally, the iPLEX reaction mix, including 
iPLEX Buffer Plus, iPLEX Termination Mix, Extended Primers mix, and iPLEX 
enzyme (Agena Bioscience, Hamburg, Germany), was added to the PCR 
amplification products. The iPLEX reaction was carried out in the following 
conditions: at 94 °C for 30 s; 40 cycles at 94 °C for 5 s [52 °C for 5 s and 80 °C 
for 5 s (repeated five times per cycle)]; and a final extension step at 72 °C for 3 
min. The samples were desalted by resin treatment and spotted on a 
SpectroCHIP (Agena Bioscience, Hamburg, Germany). The chip was analysed 
by mass spectrometry. The spectrum profiles generated by MALDI-TOF-MS 
were acquired and examined with SpectroTYPER 4.0 software (Sequenom, Inc., 
San Diego, CA). 
 
4.7 Determination of MGMT promoter methylation status  
Tumor DNAs were subjected to sodium bisulphite conversion using the EZ 
DNA Methylation-Gold Kit (Zymo Research Corporation, Irvine, CA, USA). A 
total of 50–100 ng of the bisulphite-treated DNA was amplified PCR using 
10pmol of forward (5’-GTTTYGGATATGTTGGGATAG-3’) and reverse 
primers (5’-bioCRACCCAAACACTCACCAAA-3’). The PCR conditions for 
MGMT gene were: 95°C for 5 minutes, 45 cycles of 95°C for 30 seconds, 56°C 
for 30 seconds and 72°C for 20 seconds; at the end of this cycles, a final 
elongation step was performed at 72°C for 5 minutes. Quantitative DNA 
methylation analysis of 10 CpGs (CpGs 74-83) [23] was performed on the Pyro 
Mark ID instrument using the Pyro Gold Reagents and 1 pmol of sequencing 
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primer (5’-GATAGTTYGYGTTTTTAGAA-3’). Data were analyzed with the 
support of the Q-CpG software v1.09 (Qiagen, Hilden, Germany). 
 
4.8 Establishment of primary cultures of GSCs  
After surgical removal, tumor samples of 57 patients were placed in D-PBS 
supplemented with 1% penicillin/streptomycin (Sigma-Aldrich, Basel, 
Switzerland). GSCs were isolated essentially as previously described (Salmaggi 
et al., 2006, Riccitelli et al., 2013; Marfia et al.,2014), with some modifications. 
In particular, samples were mechanically dissociated in a Petri dish with a 
scalpel, and suspension was collected with D-PBS, and centrifuged (300g for 10 
min). The pellet was enzymatically digested by treatment with 0.25% Liberase 
Blendzyme2 (Roche Diagnostics, Indianapolis, USA) in D-PBS for 4h. After 
dilution with D-PBS, the suspension was centrifuged as above. Cells were then 
resuspended in Stem Cell Medium (SCM), consisting of Dulbecco’s modified 
Eagle’s medium (DMEM)/F12 (1:1) containing 10 ng/mL fibroblast growth 
factor-2 (bFGF) (Peprotech Inc. Rocky Hill, NY, USA), 20 ng/mL epidermal 
growth factor (EGF) (R&D Systems, Minneapolis, USA), and 1% 
penicillin/streptomycin. Cells were then seeded in 75-cm
2
 flasks, and grown in a 
humidified incubator containing 5% CO2 and 5% O2 at 37°C.  
Primary cultures of GBM cells were obtained from an aliquot of the pellet 
obtained from tumor specimens as described above. Cells were plated in DMEM 
supplemented with 10% fetal bovine serum (FBS) (v/v), 2 mM L-glutamine, 100 
units/mL penicillin, 100 lg/mL streptomycin, and 0.25 lg/mL amphotericin B 
and incubated at 37°C in 5% CO2 humidified atmosphere. 
Culture medium of both GSCs and GBM cells was refreshed twice per week to 
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guarantee constant supply of required growth factors and nutrients. Both cell 
types were detached and dissociated weekly using Tryple Select (Gibco, Grand 
Island, NY, USA). 
Cells were observed with an inverted phase-contrast microscope (Nikon Eclipse 
TE300, Nikon, Shinjuku, Tokyo, Japan), and images were acquired with a 
digital camera (Zeiss Axiovision, Zeiss, Oberkochen, Germany), using Axion 
Vision software (Zeiss).Cell viability was evaluated by Trypan Blue dye-
exclusion assay, and cells counted in a Fuchs-Rosenthal chamber. 
 
4.9 Selection of two lines representative of slow- and fast-proliferating GSCs 
From 57 GBM tissue samples, we isolated 30 GSC lines and two of them, as 
representative of slow- and fast-proliferating cells were selected. The two GSC 
lines derived respectively from two patients (pts): pt1 (as slow proliferating 
cells) and pt2 (as fast proliferating cells), displaying the following features: 
aging 56 (pt 1), and 59 years (pt 2), and the preoperative Karnofsky performance 
status (KPS) was normal (100%) in pt 1, and low (60%) in pt 2.  
 
4.10 Immunophenotypic analyses 
Immunophenotypic analyses of GSCs were performed by FACS, using single 
cell suspensions. For each analysis, 5.0x10
4
 cells were incubated with the 
appropriate phycoerytrine- (PE) or fluorescein isothiocyanate- (FITC) 
conjugated antibody to evaluate the expression of the following pattern of 
stemness and endothelial progenitor markers: CD15, CD31, CD34, CD45, 
CD133 (Miltenyi Biotec, Bisley, Surrey, UK), and CD90 (Millipore Temecula, 
CA, USA). Isotype-matched mouse immunoglobulins were used as control. 
45 
 
After 30 min at 4° C, cells were washed once with D-PBS, centrifuged at 300g 
for 10 min, and finally fixed with 4% PFA. Cell analyses were performed on a 
FACS flow cytometer and CellQuest software (BD Biosciences, San Jose, CA). 
A Forward Scatter vs. Side Scatter dot plot was used to include only viable 
nucleated cells. Post-processing data analyses were performed with FlowJo 
software (Treestar, Inc. Ashland). At least 2x10
4
 events per sample were 
acquired.  
 
4.11 GCS proliferation assays 
GSCs were plated in 12-well multiplates (3.0 x 10
5
 cells/well) in SCM, and 
incubated in 5% CO2 and 5% O2 at 37°C for 7 days. At the end, cells were 
collected and centrifuged (300g, 10 min). The supernatant was discarded, and 
the pellet was re-suspended in 400 μL of TrypLE Select (Gibco) and incubated 
at 37° C for 5 min. The suspension was then mechanically dissociated by 
pipetting up and down for 2 min at room temperature, then neutralized with an 
equal volume of SCM, and centrifuged as above. Viable cells were then counted 
by Trypan Blue dye-exclusion assay, using a Fuchs-Rosenthal chamber. Growth 
curves were obtained by counting the number of viable cells at each passage one 
week after plating. To evaluate the proliferation index, GSCs were plated in 
SCM as above, and the index was calculated by dividing the cell number at 
specific time points (2 and 7 days) and the number of input cells at time 0.  
 
4.12 Cell cycle analysis 
Cells (5.0x10
5
) were fixed in one mL of cold ethanol (70% vol/vol in D-PBS) 
with gentle vortexing (5 sec) to obtain a mono-dispersed cell suspension, and 
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maintained in ethanol, at 4° C, for at least 2 h. Cells were then centrifuged 
(300g, 10 min) and the ethanol thoroughly decanted. The pellet was re-
suspended in 500 µL of D-PBS and incubated with 10 µg/mL RNAse A, at 37° 
C for 15 min. After centrifugation as above, the new pellet was resuspended in 
500 µL of D-PBS containing 50 µg/mL propidium iodide, and incubated at 
37°C, 20 min in the dark. Cell cycle distribution was measured on a 
FACSCalibur flow cytometer, and data analyzed using Cell Quest software (BD 
Biosciences, San Jose, CA). 
 
4.13 Intracranial xenograft studies  
To assess in vivo tumor formation and growth, adult 6-week old NOD-SCID 
mice (Charles River, Calco, Lecco, Italy) were used for transplants. We 
minimized the number of animals used in experiments and did great efforts to 
reduce their sufferings. All surgical procedures were performed under sterile 
conditions and aseptic manner, and were performed according to NIH and 
institutional guidelines for animal care and handling. Animals (n=5 for each cell 
line) were deeply anaesthetized, and cells were injected stereotactically into the 
frontal lobe, essentially as we previously described (Salmaggi et al., 2006). In 
detail, a burr hole was made in the skull 1.2 mm lateral to the bregma using a 
drill, and 2.0x10
5
 cells in 2 µl of PBS were stereotactically injected over 3 min at 
a depth of 4 mm. At 5 weeks mice were anesthetized and transcardially perfused 
with 4% paraformaldehyde in  saline. The brains were removed, post-fixed and 
prepared for histology (Salmaggi et al., 2006). Tumor volume was calculated by 
measuring the diameter and length of each tumor in the respective slide with the 
maximum tumor size (Schmidt et al., 2004). Maximal and minimal diameter of 
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the tumor was measured in mm on Hematoxylin and Eosin (H&E) stained 
sections and the approximate tumor volume was calculated using the following 
formula: tumor volume (mm
3
) = (max. diameter) x (min. diameter)
2
 x 0.5.  
In order to identify human cells, slides were labeled with a specific mouse anti-
human nuclei antibody (MAB 1281, Chemicon) (1:50, overnight at 4°C). Next 
they were washed and incubated with secondary antibody Cy-3-conjugated 
antimouse IgG (1:1000, Jackson, Bar Harbor, Maine, USA) for 1 h at room 
temperature and then washed again and counter stained with 4’-6-diamidino-2-
phenylindole (DAPI) to identify cell nuclei. Immunofluorescence measurements 
were made using a confocal microscopy (Leica System, Wetzlar, Germany). 
 
4.14 Metabolic Studies by Cell Labeling 
Metabolic studies using [C3-3H]-D-erythro-sphingosine (3H-Sph) (PerkinElmer, 
Boston, MA, USA) were performed as previously reported (Riboni et al., 2000), 
with some modifications. In detail, at the time of experiment, cells were plated 
in 6-multiwell plates (5.0 x 10
5
 cells/well), and incubated for a given period of 
time in complete SCM containing 20 nM–1µM 3H-Sph (0.4 µCi/mL) and 
phosphatase inhibitors (Riccitelli et al., 2013). After exposure to 3HSph for 
different times, GSCs were centrifuged (500g, 5 min at 4°C), and media and 
cells were collected. Cellular internalization of Sph was confirmed by 
radioactivity counting, and possible cytotoxic effects were excluded by a cell 
viability assay. 
 
4.15 Sphingolipid and S1P Extraction and Purification 
Total lipids were extracted from cells with chloroform/methanol at 4°C as 
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previously reported (Anelli et al., 2005). Briefly, after partitioning of the total 
lipid extract, the upper alkaline aqueous phase (containing S1P) was evaporated 
under a nitrogen stream and counted for radioactivity. The lower organic phase 
(containing Ceramide, sphingomyelin, and neutral glycosphingolipids) was 
subjected to a mild alkaline hydrolysis by the addition of 0.15 volumes of 0.1 M 
NH4OH, and the phases were then separated by centrifugation. 
Extracellular S1P was extracted and partially purified from cell medium by a 
two-step partitioning, at first in alkaline conditions; then a back extraction of the 
aqueous phase was carried out in acidic conditions (Anelli et al., 2005). The 
final organic phase, containing extracellular S1P, was then evaporated under a 
nitrogen stream. 
 
4.16 Separation and Quantification of Sph Metabolites 
Sphingolipids in the methanolysed organic phase and aqueous phases were 
counted for radioactivity by liquid scintillation, and applied to silica gel HPTLC 
plates (Merck, Darmstadt, Germany). The plates were developed in 
chloroform/methanol/water (55:20:3, by vol.) for the organic phase. For the 
quantification of 
3
H-SlP, the fractions containing cellular and extracellular S1P 
were applied to HPTLC plates and developed in n-butanol/acetic acid/water 
(3:1:1, by vol.). Standard 
3
H-S1P, obtained from 
3
H-Sph by enzymatic 
phosphorylation (Anelli et al., 2005), was chromatographed on the same plate, 
and used as internal standard. 
At the end of the chromatographic separation, HPTLC plates were submitted to 
digital autoradiography (Beta-Imager 2000, Biospace, Paris, France). The 
radioactivity associated with individual sphingolipids was determined with the 
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β-Vision analysis software provided by Biospace. The recognition and 
identification of radioactive Cer, sphingomyelin, glucosyl-ceramide (Glc-Cer), 
and S1P were performed as previously reported (Anelli et al., 2005; Riboni et 
al., 2000). 
3
H-S1P degradation was quantified as tritiated water in the final 
aqueous phase of medium partitioning. To this purpose, aliquots of the aqueous 
phase of the partitioned media were submitted to fractional distillation (Anelli et 
al., 2005), and counted for radioactivity as above. 
 
4.17 Cell Treatments on GSCs  
For S1P treatment, stock solution of S1P (100 mM) (Enzo Life Sciences, 
Farmingdale, NY, USA) was prepared in fatty acid free bovine serum albumin 
(4 mg/mL in D-PBS). For FTY720 treatment, FTY720 (Cayman Chemicals, 
Ann Arbor, MI, USA) was dissolved in absolute ethanol at a concentration of 5 
mM. For TMZ treatment, TMZ (Schering- Plough, Segrate, Milan, Italy) was 
dissolved in DMSO. At the time of the experiments, stock solutions were diluted 
at 200nM (S1P), 100μM (TMZ) and 100nM (FTY720) final concentrations in 
fresh SCM and administered to cells. After incubation for 48h, the number of 
viable cells, the apoptotic and necrotic events, the proliferation index, and the 
cell cycle were analyzed. 
 
4.18 Assessment of Apoptosis 
To evaluate apoptosis, GSCs were processed by human Annexin VFITC kit 
(BMS306FI, Bender MedSystems, Vienna, Austria). Briefly, cells were 
collected, washed in cold D-PBS and resuspended in 200mL of binding buffer 
(10mM Hepes/NaOH, pH 7.4, 140mM NaCl, 2.5mM CaCl2) containing 5 mL of 
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Annexin VFITC solution. The mixture was incubated for 10 min in the dark at 
room temperature, and at the end, 1 mL of binding buffer was added. After 
washing with D-PBS, the final cell pellet was resuspended in 200 mL of binding 
buffer, containing 1mg/mL propidium iodide), and samples were immediately 
analysed by flow cytometry. This double staining procedure allowed us to 
distinguish early stage apoptotic cells (Annexin V1/Propidium Iodide-), from 
late stage apoptotic cells (Annexin V1/Propidium Iodide1), and necrotic cells 
(Annexin V-/Propidium Iodide1). Data were acquired by a FACS flow 
cytometer and analyzed by CellQuest software (BD Bioscence, San Jose, CA). 
 
4.19 Analysis of cell viability 
Cell viability was determined by MTT assay. GSCs were seeded at 2x10
4
 
cells/cm
2
. The day after, cells were treated with different treatments for the 48 
hours. The medium was then replaced by MTT dissolved in fresh medium (0.8 
mg/ml) for 4 hours. Then GSCs were incubated 10 minutes in 
isopropanol/formic acid (95: 5 v/v) to solubilisation of formazan crystal, and the 
absorbance (570nm) was measured using a microplate reader (Wallack 
Multilabel Counter, PerkinElmer, Boston, MA, USA). 
 
4.20 Assessment of autophagy 
Cells were grown on a chamber slid and, after different treatments, were 
incubated with 1µg/mL acridine orange (Sigma-Aldrich, St Louis, MO) (15 min) 
and then with 5µM Hoechst 33342 (Sigma-Aldrich, St Louis, MO) (15 min).  
The sample was mounted with ProLong® Gold Antifade Mountant 
(LifeTechnologies) and images were capture using a Leica TCS SP5 confocal 
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microscope (Leica Microsystems, Wetzlar, Germany). Cells were counted in 
three microscopic fields in each well (three wells per treatment) and expressed as 
a percentage of the total number of cells. Each treatment was performed in 
triplicate.  
 
4.21 Immunoblot analysis 
Cell lysates (60 μg of proteins) of GSCs were analysed by immunoblotting with 
anti- LC3B and anti-GAPDH antibodies. In detail, GSC lines were lysed in the 
presence of a complete protease inhibitors cocktail with 20mM Tris-Cl (pH 7.4), 
1% Triton X-100, 100mM NaCl, 1mM EGTA, 2mM MgCl2, 5mM β-glycerol-
phosphate, 2 mM Na-pyrophosphate, 2 mM Na-orthovanadate, 1 mM DTT, 
1mM NaF, and 1mM PMSF. Cell proteins were resolved by SDSPAGE on 18% 
gels. The membranes were then blocked in 5% milk using TBS-Tween 0.1%, 
incubated for 1 hr at room temperature with  anti-LC3B (1:1000) (Sigma, St 
Louis, MO), and then with horseradish peroxidase-linked secondary antibody for 
30 minutes at room temperature. Bound antibody was visualized by ECL 
(Supersignal West Pico, Pierce Biochemicals, Rockford, IL, USA), and 
membranes were exposed to Kodak Biomax film. 
 
4.22 Statistical Analyses 
The data are shown as mean ± standard deviation (SD) of at least three 
independent experiments, performed in triplicate using separate culture 
preparations. The statistical significance was determined by the two-tailed 
Student’s t test. Differences were considered statistically significant at P<0.05. 
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Moreover, continuous variables were expressed as median values and 
interquartile ranges (IQR), and compared by the Mann-Whitney U-test. 
Categorical variables were expressed as frequencies and percent values, and 
compared by the chi-squared test. Mortality rates with 95% confidence intervals 
(95%CI) were calculated as the number of events per 1 person-year. For the 
same purpose the tumor volume was categorized by choosing as cut-off the 
median value observed in the study population (i.e., 25 cm
3
). Rho correlation 
coefficients were calculated by the Spearman’s test. The Cox proportional 
hazard model was used to estimate potential risk factors of death and the effect 
of each variable was adjusted for the others in the multivariate model. In this 
model death was the event and follow-up duration was the time variable. The 
follow-up period for each patient was calculated starting from date of diagnosis 
to death or last visit at time of medical files review, whichever came first. The 
results were expressed as crude and adjusted hazard ratios (cHR and aHR) with 
95%CI. Starting with the full model, stepwise backward elimination was used as 
a variable selection procedure. A nominal α level of 0.10 as a cut-off for 
removing variables was considered. All p values reported are two-sided and a 
value <0.05 was considered statistically significant. All analyses were done with 
SPSS software (release 21.0, IBM Corp., Armonk, New York).  
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RESULTS 
5.1 Patients 
Overall 57 patients who underwent neurosurgical procedures for GBM between 
February 2012 and June 2015 were included in the study. All patients underwent 
surgical resection of the lesion. The main characteristics of the 57 patients at 
study entry are reported in Table 3. Overall the median preoperative KPS was 80 
(IQR: 70-90) and it was inversely correlated with age (r=-0.43, p<0.0001). In 
GBM patients the volume of the tumoral lesion was calculated from magnetic 
resonance imaging and the median tumor volume was 25.6 cm
3
 (IQR: 8.0-45.3). 
The tumoral volume was calculated as mean of 25.8 cm
3
 (IQR: 8.0-45.0).  
 
5.2 Survival analysis in patients with Glioblastoma 
A survival analysis was also performed in a subgroup of 57 patients with 
Glioblastoma (i.e. grade IV WHO glioma). During the follow-up 34 patients 
(60%) died after a median of 0.8 years (IQR: 0.4-1.4) from diagnosis with a 
mortality rate of 0.4 per person-year (95%CI 0.3-0.6). The main characteristics 
of this patient group are shown in Table 3. The genetic and epigenetic pattern of 
these patients was characterized by the presence of 1p/19q co-deletion in 2 
patients (3%), an unmethylated status of MGMT promoter in 28 (49%) and a 
wild type IDH1/2 in 39 (68%). 
The cumulative 1-year survival was shorter in patients with a tumor volume > 25 
cm
3
 (46 vs 83% in those with tumor volume < 25 cm
3
; p=0.02). No difference in 
the survival rate was found by comparing patients with methylated and 
unmethylated MGMT promoter. By univariate Cox regression analysis age > 60 
years at time of surgery (cHR 2.6; 95%CI 1.4-4.9), preoperative KPS < 70 (cHR 
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2.5; 95%CI 1.2-5.5), a tumor volume > 25 cm
3
 (cHR 2.1; 95%CI 1.1-4.2) and 
wild type IDH1/2 (cHR 4.8; 95%CI 1.3-16.9) resulted risk factors of decreased 
survival. Owing to the small sample size no multivariate analysis was performed 
in this group. 
Interesting, the tumor volume was significantly bigger in patients who died than 
in those who were survivors at the end of the follow-up period (median 32.5 vs 
23.4 cm
3
; IQR: 16.3-53.0 vs 6.4-35.0, respectively; p=0.04). 
 
TABLE 3: Main characteristics of the GBM patients included in the study 
 Patient with GBM 
(n=57) 
Male sex (%) 41 
Meadian age at the study entry, yrs 
(IQR) 
61 (48–71) 
Median follow-up duration*, yrs 
(IQR) 
0.9 (0.4-1.5) 
Patient alive at the end of follow-up 
(%) 
30 (45) 
yrs: years; IQR: interquartile range 
*Follow-up duration was calculated from the date of diagnosis to date of death or 
last follow-up visit whichever came first. 
 
5.3 Genomic and epigenetic results 
The 1p/19q co-deletion was detected in 5% of GBM patients; while the R132H 
mutation of IDH1 were found in the 15% of our patients. Also the median rate of 
methylation of the MGMT promoter was identified in 8% of GBM patients 
(IQR: 4-26).  
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5.4 Histological analysis and proliferative features of human GBMs 
Microscopically, GBM specimens were composed of poorly differentiated glial 
cells, with numerous multinucleated giant cells. Confluent areas of necrosis and 
parenchymal destruction with serpiginous foci were present. Vascular 
proliferation was seen throughout the lesions, often around necrotic areas and in 
peripheral zones of infiltration. Diffuse reactivity for GFAP, regularly 
distributed, was seen in both cases. Proliferative activity was prominent, with 
detectable mitosis in nearly every field. Areas with large number of Ki67 stained 
nuclei in brown, reflecting active cellular proliferation, (Fig. 5A). The mean 
value of Ki67 labeling index, determined by the Ki-67antibody, was 3410 %.  
We isolated with a success rate of 52.6%, 30 GSC lines from 57 initial GBM 
specimens. We characterized cells for stemness, growth capability, tumorigenic 
potential, and surface marker expression.  
 
5.5 Selection of two GSC lines, as representative of two group with different 
proliferation rate. 
We investigated the proliferation behavior of our GSC lines. As shown in figure 
5B, we evaluated for each GSC line the number of viable cells at each passage, 
defining their proliferation capacity.  
About the proliferation rate we noticed that our cell lines behaved fundamentally 
in two different ways, so we decided to separate GSC lines into two groups:  i) 
slow proliferating group and ii) fast proliferating group (Figure 5B)  . 
Following our hypothesis that S1P and its metabolism play a crucial role in 
GBM aggressiveness, favoring the proliferation of GSCs and sustaining the 
tumor  microenvironment, we selected two GSC lines as representative of the 
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two distinct groups. GSCs obtained from slow proliferating group was called 
SC01 and the other, selected among fast proliferation GSC lines was called 
SC02.   
 
FIGURE 5: Ki-67 immunoreactivity of GBMs and GSC growth curves. A: 
Tumor tissue from SC02 stained with anti-Ki-67 antibody. The image shows 
positive nuclear expression of Ki-67 in brown and negative nuclei 
counterstained in blue (magnification, 40x). B: the graphic illustrate  growth 
curves of slow- and fast-proliferating groups, showing the number of viable cells 
at each passages.  
 
 
5.6 SC01 and SC02 grow as neurospheres and exhibit in vivo tumorigenic 
potential 
In appropriate culture conditions that favor GSC survival and proliferation, 
GBM-derived cancer cell lines from slow- and fast-proliferating groups formed 
GSCs that grew as free floating clusters, namely neurospheres (Figure 6A and 
6B, respectively). GSCs were next validated in vivo for their tumorigenic 
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potential in immunodeficient mice. After intracranial injection, both GSC lines 
formed tumors in all injected mice (Figure 6C). The mean tumor volume ± SD at 
sacrifice was 9.1 ± 4.8 mm
3
 and 12.9 ± 5.5 mm
3
 in SC01 and SC02, respectively 
(Figure 6D). 
The human origin of the tumor was demonstrated by the positive staining with 
an anti-human nuclei antibody, which identified cells positive to human marker 
in the slides (Salmaggi et al., 2006). These results, showing that both cell lines 
exhibit the capacity for sphere formation, and are tumorigenic in brains of 
immunocompromised mice, demonstrated that SC01 and SC02 expressed 
functional features of GSCs (Singh et al., 2004). 
 
 
 
FIGURE 6:  Stem cell features of GSC lines. Representative microscopic 
image of GSCs grown as neurospheres of (A) slow- and (B) fast-proliferating 
GSC lines (magnification, 200x). (C) Representative histological image 
(hematoxylin and eosin staining) and (D) graphic representation of a brain tumor 
A B 
C D 
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derived from GSCs after intracranial orthotopic xenograft of nude mice. 
 
 
5.7 SC01 and SC02 neurospheres differ in the expression of stemness markers 
In order to phenotype SC01 and SC02, we determined the expression of different 
putative stem/progenitor cell markers. As shown in Fig. 7, all the investigated 
makers were highly expressed in both GSCs, with CD90 as the highest (>90%) 
expressed one. It should be noted that CD90 has been recently identified as a 
novel marker for GSCs in high-grade gliomas and as a more general marker than 
the recognized GSC marker CD133 (He et al., 2012). The expression of all other 
markers, including CD133 and CD15, was significantly higher in SC02 than 
SC01.  
 
 
FIGURE 7: Slow- and fast-proliferating GSCs growing as neurospheres 
differ in stemness marker expression. The expression of different stemness 
and precursor markers in SC01 (grey) and SC02 (black) cells, obtained by 
cytofluorimetric analyses is shown. Data are expressed as % of total cells and 
are the mean ±SD of 3–5 independent experiments. *P<0.05; **P<0.01; 
***P<0.001 SC02 versus SC01. Similar data were obtained at different cell 
passages. 
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5.8 SC01 and SC02 differ in the proliferation rate and cell cycle parameters 
In the used culture condition, the analyses of the cellular growth curves showed 
that, along with passages, the cell number gradually increased, and this increase 
was much more pronounced in the SC02 line (Fig. 8A). Moreover, at both 2 and 
7 days in culture, the proliferation index was significantly higher in SC02 than 
SC01 (Fig. 8B). 
The results of the cell cycle evaluation by flow cytometry revealed differences in 
the number of cells undergoing mitosis between the two cell lines. In fact, when 
compared with SC01 (Fig. 8C), the SC02 cell line (Fig. 8D) exhibited a 
significant increase in the percentage of cells in the mitotic phases and a 
decrease in that of cells in G0/G1 phase.  
 
FIGURE 8: Slow- and fast-proliferating GSCs differ in proliferation and 
cell cycle parameters. (A): SC01 and SC02 were plated at the same initial 
density, and at each passage viable cells were counted; (B) GSCs at the 5th 
passage were plated, and after 2 and 7 days in culture, the proliferation index 
was calculated as described in “Materials and Methods”; GSCs from (C) SC01, 
and (D) SC02, were plated as above, and cell cycle distribution was analyzed by 
flow cytometry. Similar data were obtained at different cell passages. *P<0.05; 
**P<0.01; ***P<0.001, SC02 versus SC01. 
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5.9 SC01 and SC02 Differ in Sph Metabolism and Extracellular Release of 
S1P 
To follow S1P metabolism and its breakdown product, we used Sph labeled with 
tritium at the C3 position of the long chain base backbone. This label remains in 
the lipid throughout the phosphorylation and recycling steps of the sphingoid 
base, and thus allows tracking of all metabolites as long as the sphingoid 
backbone remains intact, as well as S1P irreversible degradation as tritiated 
water. After administration, tritiated Sph was rapidly incorporated into the two 
GSC lines in a time-dependent fashion, and, after 120 min, total incorporated 
radioactivity accounted for 197.9±20.7 in SC01, and 214.2±19.8 nCi/dish in 
SC02, that is approximately half of the administered radioactivity. At all 
investigated times, the level of intracellular 3H-Sph was found low, representing 
less than 10% of the total incorporated radioactivity in both cell lines, this level 
being 3-, 4-fold higher in SC01 than that of SC02 cells (Fig. 9). These data 
indicate that both GSC types are able to rapidly incorporate and metabolize 
exogenous Sph, and that the SC02 cells are particularly efficient in this 
metabolization. 
At different pulse times, the bulk of incorporated radioactivity was associated to 
the N-acylated derivatives of Sph, and, in less amounts, to the 1-phosphorylation 
products (Fig. 9).  
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FIGURE 9: Slow- and fast-proliferating GSCs differ in Sph metabolism. 
SC01 (grey bar) and SC02 (black bar) cells were pulsed with 20 nM 3H-Sph for 
15–120 min. At the end, cells and media were processed and analyzed as 
described in “Materials and Methods”. The radioactivity distribution (as % of 
total incorporated radioactivity) among unmetabolized Sph, and its N-acylation, 
and 1-phosphorylation products is shown at (A) 15 minutes, (B) 30 minutes, (C) 
120 minutes. Data are the mean of three experiments, performed in duplicate. *P 
< 0.05; ***P < 0.001, SC02 versus SC01. 
 
It is worth noting that the ratio between N-acylated and 1-phosphorylated 
metabolites was 21.3 and 15.5 in SC01, and 5.2 and 4.9 in SC02 at 15 and 120 
min, respectively.  
The main N-acylated metabolites produced during pulse in both GSC lines were 
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represented by Cer and complex sphingolipids, including sphingomyelin, and, in 
much lower amounts, Glc-Cer. All over pulse, Cer was by far the major 
3
H-
metabolite, its anabolic derivatives increasing with time (Fig. 10). A significant 
decrease in 
3
H-Cer in SC02 compared with SC01 was observed after 120 min 
pulse (Fig. 10A). All over pulse, in SC02 cells a marked elevation of 
sphingomyelin and Glc-Cer was also evident ( Fig. 10B).; at 120 min, in SC02 
these sphingolipids increased by about 110% and 250%, respectively, relative to 
SC01 (Fig. 10C). As reported above, the metabolites derived from the 1-
phosphorylation process represented the second class of Sph derivatives (Fig. 9).  
 
 
FIGURE 10: Cer consumption to SM and Glc-Cer is enhanced in fast-
proliferating GSCs. Content of labeled Cer (A), sphingomyelin (B), and Glc-
Cer (C) in SC01 (light grey) and SC02 (dark) at 15–120 min pulse with 3H-Sph. 
Data are expressed as percent of N-acylated metabolites, and are the mean6SD 
of 3 experiments. **P < 0.01; ***P < 0.001, SC02 versus SC01. 
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Among them, intracellular S1P represented only a minor fraction of 1-
phosphorylated Sph metabolites and, at 15 min pulse, its level was significantly 
lower in SC01 than SC02 (Fig. 11A). Thereafter, there was no relevant change 
in the cellular S1P level between SC01 and SC02. At all investigated times, 
tritiated water, represented the vast majority of Sph 1-phosphorylation products, 
its content being significantly higher (4-, 6-fold) in SC02 than in SC01 (Fig. 
11B). After pulse with [C3-
3
H]Sph, tritiated water derives from the oxidation of 
tritiated hexadecenal produced from 
3
H-S1P by S1P lyase (Anelli et al., 2005). 
Our results indicate that a rapid and efficient degradation of S1P, derived from 
the phosphorylation of exogenous Sph, occurs in GSCs. Besides tritiated water, 
the analyses of the culture media from both cell lines revealed the presence of 
labeled S1P (Fig. 11C,D), which increased in a time-dependent fashion in both 
cell lines. Remarkably, at all investigated times, the S1P levels in the 
extracellular milieu of SC02 were significantly higher than those of SC01 (Fig. 
11C). At 120 min pulse extracellular S1P from SC02 accounted for about 4-fold 
that of intracellular S1P, and about 9-fold that of SC01 (P<0.001). 
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FIGURE 11: Slow- and fast-proliferating GSCs differ in S1P degradation 
and export. The radioactivity associated to (A) intracellular S1P (S1Pin), (B) 
water, and (C) extracellular S1P (S1Pout) in SC01 (dotted line) and SC02 
(straight line) is shown at 15–120 min pulse with 3H-Sph. Results are expressed 
as nCi/well, and are the mean6SD of three experiments in duplicate. **P< 0.01; 
***P< 0.001, SC02 versus SC01. D: Representative autoradiographic image of 
the extracellular S1P containing fractions from SC01 and SC02, after 15–120 
min pulse. 
 
5.10 Extracellular Secretion of S1P by SC Cells is Highly Efficient and 
Stimulated by Growth Factors 
To better define the S1P export from GSCs, we next addressed the possibility 
that elevated levels of Sph might influence its metabolism and S1P export. After 
pulse of GSCs with 1 mM Sph, the percentage of phosphorylated metabolites, 
including both intracellular S1P and its catabolic product water, increased in 
respect with the N-acylated ones in both cell lines. In the presence of 1 mM Sph, 
the amount of released S1P was relevant, reaching on average the concentration 
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of 2 nM in both cell lines. Since EGF and bFGF are recognized as autocrine 
signals in GSCs, we then evaluated the possible influence of these growth 
factors on S1P release. The results demonstrated that either in the absence or 
presence of EGF and bFGF, GSCs can release S1P, reflecting a constitutive S1P 
secretion by the cells. It is relevant to note that this secretion was significantly 
enhanced by the presence of EGF and bFGF (Fig. 12A,B), supporting an 
autocrine loop induced by these growth factors. 
 
FIGURE 12: Growth factors stimulate S1P export by GSCs. GSCs were 
pulsed with 20 nM 3H-Sph in SCM without (- GFs) or with (+ GFs) EGF and 
bFGF for 120 min. A: Representative autoradiographic image of the 
extracellular S1P containing fractions from SC01 and SC02, separated by 
HPTLC. B: Radioactivity associated to extracellular S1P (S1Pout) is expressed 
as nCi/well and is the mean6SD of three experiments. **P<0.01; 
***P<0.001,+GFs versus - GFs. 
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5.11 Extracellular S1P Prompts GSC Proliferation and Stemness 
On the basis of the above results, it was of interest to investigate whether 
extracellular S1P can influence the GSC proliferation index and/or stemness. In 
this scenario, GSCs were cultured in S1P-enriched SCM medium for 48 h, and 
the number of viable cells was determined. As shown in Fig. 13A, the addition 
of S1P resulted in a significant increase in viable cells compared with the control 
group (P<0.01). These results suggest that extracellular S1P promotes GSC 
survival and/or proliferation. Trypan blue exclusion test revealed that few cells 
(less than 5%) were stained in control and S1P treated cells. Cytofluorimetric 
studies were performed. These studies, besides confirming the low level of dead 
cells in both control and S1P-treated cells, demonstrated that the number of cells 
in the early and late apoptosis, as well as the necrotic one was significantly 
reduced after S1P administration (Fig. 13B). However, due to the low levels of 
death cells, it is unlikely that the increase in cell number in S1P treated cells 
results from reduced apoptosis/necrosis, and it may indicate an effect on cell 
cycle progression. We then performed FACS analyses to determine the cell 
cycle profile in S1P-treated cells. After culturing in S1P-containing medium, 
quantitative analysis showed that cells in the G0/G1 phase decreased and those 
in the S and G2/M phases significantly increased (Fig. 13C), suggesting that 
GSCs cultured in S1P containing medium transitioned from the G1 phase to the 
S and G2/M phases of the cell cycle. In agreement, we found that the 
proliferation index of S1P-treated cells was increased significantly in 
comparison with cells that did not receive the sphingoid molecule, and this effect 
was inhibited by FTY720 (Fig. 13D). Taken together, these results point out that 
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extracellular S1P, after binding to S1PRs, promotes GSC survival and 
proliferation.  
In order to evaluate if the proliferating effect of S1P was selective for GSCs or 
shared with non-stem GBM cells, we prepared primary cultures of GBM cells 
from tumor samples from pt 1 and 2, and evaluated the effect of S1P on their 
proliferation. These experiments demonstrated that 200 nM S1P significantly 
increased the proliferation of GBM cells from pt 1 and pt 2, by 26.8% and 
38.2%, respectively (P<0.01 in both cases). 
 
 
FIGURE 13: Extracellular S1P promotes GSC survival and proliferation. 
SC02 cells were treated in the absence (Ct) or presence of 200 nM S1P alone 
(S1P) or with 100 nM FTY720 (S1P1+FTY) for 48 hours. At the end, cell 
viability (A), apoptosis (B), cell cycle parameters (C), and proliferation index 
(PI) (D) were assessed as reported in “Materials and Methods”. *P<0.05; 
**P<0.01; ***P<0.001, S1P-treated versus Ct. Similar effects of S1P were 
obtained on SC01 cells. 
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Finally, we evaluated the effect of nanomolar concentrations of S1P on cell 
stemness. Remarkably, the results of the phenotypic characterization by FACS 
analyses demonstrated that S1P significantly increased the expression of 
different stemness and precursor markers in GSCs (Fig. 14A), including, among 
others, CD133 and CD15. This S1P effect could be due to either an induction of 
stem cell marker expression or a selective expansion of cells that are already 
expressing stem cell markers. In order to clarify this point, we evaluated the 
effect of S1P on stem marker expression in primary cultures of GBM cells 
prepared from pt 1 and 2. We first found that primary GBM cells express very 
low levels of stemness markers. Indeed, as shown in Fig. 14B, the percentages of 
CD133 and CD151 cells in GBM cells from pt 2 were by far lower (15- and 25-
fold) the corresponding value of SC02, their corresponding GSCs (Fig. 13A). 
We found similar differences in the stem marker expression by GBM cells from 
pt 1 and SC01. Of relevance, and differently from what we observed in GSCs, 
S1P exerted only modest, if any, effect on the stemness profile of primary GBM 
cells (Fig. 14B). 
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FIGURE 14: Extracellular S1P enhances GSC stemness in GSCs but not in 
GBM cells. (A) SC02 cells and GBM cells from pt 2 (B) were incubated in the 
absence (Ct) or presence of 200 nM S1P (S1P) for 48 h. At the end, the 
immunophenotypic profile was assessed by cytofluorimetric analyses. Results 
are expressed as percent of total cells and are the mean ± SD of three 
independent experiments. **P < 0.01; ***P < 0.001, S1P treated versus Ct. 
Similar effects of S1P were observed on SC01 and GBM cells from pt 1. 
 
5.12 Combined treatment: TMZ and FTY720 induced GSC death through the 
activation of  autophagic death.  
We next speculated that FTY720  might augment the effect of TMZ on GSC 
lines, and that GCS might be involved in TMZ resistance. To test this 
hypothesis, we first analysed the effect of TMZ alone on SC01 and SC02 cell 
lines. Cells were plated on permanox glass chamber slide in SCM medium 
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(Figure 15A) and  were treated with 100μM of TMZ alone (Figure 15B) or in 
combination with 3μM of  FTY720 (Figure 15C).  Images obtained by phase 
contrast microscopy after 48 hours treatment with showed that SC01 and SC02 
cell lines maintained unchanged their morphological features. We found that the 
exposure of resistant cells to a 100μM dose of TMZ,  did not affect cell viability 
after 48h (Figure 15D).  
In order to confirm that the real effects was related to S1P production and 
release, we explored the effect of combination treatment (TMZ plus FTY720) on 
drug sensitivity. The results showed that the incubation with either TMZ and 
FTY720 lead to a significant reduction in cell viability both SC01 and SC02 
GSC lines.  
 
FIGURE 15: Effect of TMZ on cell survival. Representative images of GSCs 
morphology after 48 h treatment with vehicle (A, 0.1% DMSO) or 100 μM TMZ 
(B) alone, or in combination with 3μM FTY720 (C). Images were viewed on a 
phase contrast microscope, and digital images were acquired (magnification, 
100X). (D) GSCs were exposed to TMZ and FTY720 or vehicle. Cell viability 
was assessed after 48 h of treatment by MTT assay. Results are expressed as 
percentage of cell viability with respect to vehicle-treated cells (100%). Data are 
the mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01 vs 
vehicle-treated cells.  
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Recent studies demonstrated that TMZ-induced autophagy in apoptosis-resistant 
GBM cells (Zhang J, et al., 2015) can be the result of the activation of 
authophagic process. To evaluate whether the combination with TMZ and 
FTY720 of the exposed cells induce autophagy, we performed cell staining with 
acridine orange, in parallel to Hoechst 33342 after drug treatments. 
Results revealed that after 48 hours, no formation of acidic vesicular organelles 
was evident in GSC lines without treatment (Figure 16A-D), whrease, in TMZ-
treated cells, acridine orange staining showed an increase in the number, size, 
and strength of the bright red fluorescence spots in the cytoplasm (Figure 16E-
H) and this increase trend was observed with significant evidence in 
TMZ+FTY720 combined GSC-treated (Figure 16I-L).  
 
 
FIGURE 16: FTY720 in combination with TMZ  induces autophagic death 
in GSCs cells. Vital staining with Hoechst 33342 and acridine orange of GSCs 
treated with vehicle, (A-D), with 100μM TMZ alone (E-H), or in combination 
with 3μM FTY720 (I-L) for 48 hours. The fluorescence microscopy images 
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(original magnification, 400x) are representative of control and treated cells 
observed in three independent experiments. (M) Cell lysates (60 μg of proteins) 
were analysed by immunoblotting with anti-LC3B and anti-GAPDH antibodies. 
Similar expression was obtained in several independent experiments. (N) 
Quantification of LC3B-II expression versus GAPDH expression in GSCs 
treated with vehicle, TMZ alone or in combination with FTY720. Data are the 
mean ± SD of three independent experiments. ∗∗P<0.01; ∗∗∗P<0.001. 
  
To validate this finding, the expression level of the isoform II of the microtubule 
associated protein 1 light-chain 3B (LC3B-II), a recognized marker of autophagy 
(31), was assessed. As shown in Figure 14M, the treatment with TMZ induced a 
significant increase in the LC3B-II protein. Furthermore, the incubation with 
TMZ and FTY720, showed a more significant increased trend, this level being 
6-fold higher in combination treatment than that the vehicle one, thus confirming 
that TMZ+FTY720 induces autophagic death in GSC lines. 
  
73 
 
DISCUSSION 
Glioblastoma multiforme is the most common primary malignant brain tumor in 
adults and with the worst prognosis (Louis DN, et al., 2007). Several clinical 
predictors of survival have been identified, such as age, pre-operative functional 
status and tumor extent (Gorlia T, et al., 2008). In addition, some genetic and 
epigenetic features may be used as prognostic factors (van den Bent MJ, et al., 
2010; van den Bent MJ, et al., 2009). Nevertheless, despite many efforts to treat 
this disease, the mortality rate remains high, recurrence seems to be the rule and 
still the outcome is invariably fatal. In this light, a better understanding of the 
biological background of tumor growth and aggressiveness in patients with 
gliomas may be helpful to identify targeted therapies to achieve a better 
outcome. Malignant transformation results from the sequential accumulation of 
genetic alterations and abnormal regulation of growth factors signalling 
mediated also by sphingolipids. Moreover, the finding of a subpopulation of 
CSCs is present in the core of the tumor, has fuelled the hypothesis that these 
cells play a crucial role in proliferation, aggressiveness, and intrinsic resistance 
to therapy, being thus a key determinant driving tumor growth and relapse after 
resection (Baronchelli S, et al., 2013; Marfia G, et al., 2014). The standard of care 
for patients with newly diagnosed GBM includes maximal safe resection of the 
tumor followed by 6 week course of Radio therapy (RT) with concomitant 
systemic therapy using alkylating agent TMZ (Stupp et al., 2005 Stupp et al., 
2008; Weller M, et al., 2014). This combination has increased the survival of 
patients with GBM, but their median survival remains only about 15 months 
(Ohgaki H & Kleihues P. 2005). Standard of care approach is generally uniform 
and does not take into account different molecular and biological signatures of 
74 
 
GBM. Our study provides a contribution to this complex field.  
Indeed, a central unresolved issue with GSCs is their growth signaling and cell 
cycle control that are different from patient to patient. This lack of progress is 
especially surprising given that the histopathological assessment in the diagnosis 
of GBM includes the identification of a high tumor cell mitotic index (Persano et 
al., 2013; Pojo & Costa, 2011), as well as that a key determinant of GSCs is their 
capacity for extensive proliferation and self-renewing (Al-Hajj et al., 2004; 
Oliver and Wechsler-Reya, 2004).  
S1P is increasingly recognized as a critical growth factor for a number of cancer 
cell types and, among others, glioma cells (Yester et al., 2011). A role for S1P as 
a potential mitogenic factor in GSCs, however, remains uncharacterized. In this 
research project overall 57 patients who underwent neurosurgical procedures for 
GBM between February 2012 and June 2015 were included in the study. All 
patients underwent surgical resection of the lesion. Interesting, the tumor volume 
was significantly bigger in patients who died than in those who were survivors at 
the end of the follow-up period (median 32.5 vs 23.4 cm3; IQR: 16.3-53.0 vs 
6.4-35.0, respectively; p=0.04).  
To this purpose we investigated the origin and role for S1P in GSC properties 
and specifically in GSC proliferation and stemness. Among different 30 GSC 
lines prepared from 57 GBM specimens, on the bases of proliferation and 
stemness parameters, we selected two cell lines, named SC01 and SC02, as 
representative of slow- and fast-proliferating cells, respectively. Moreover the 
finding that both GSCs, in addition to the well-known stemness markers, express 
CD31, CD34, CD45, is in agreement with previous evidence in literature, 
suggesting that CD133+ cells could have an intrinsic differentiation potential 
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toward tumor cells or endothelial cells (Christensen et al., 2011; He et al., 2012). 
These GSC populations demonstrated heterogeneity not only in terms of 
proliferative potential, but also of expression of stem cell markers, the fast 
proliferative status of SC02 being paralleled by a higher expression of stemness 
and angiogenic parameters.  
It is becoming increasingly clear that GSC properties involve a complex 
interplay between GSCs and their microenvironment, and the GSC 
microenvironment provides essential cues to their maintenance (Charles et al., 
2012; Filatova et al., 2013; Heddleston et al., 2011). Further results here 
obtained underscore the relevance of the extracellular environment in affecting 
the extent of S1P export. 
Indeed, metabolic studies revealed that both GSC lines were able to efficiently 
take up and metabolize Sph, but with significant differences between slow-
proliferating and fast-proliferating cells. In particular, SC02 exhibited an 
extremely rapid Sph processing, and a significant higher ratio between 1-
phosphorylated and N-acylated metabolites than SC01, indicating that in the two 
cell lines a different propensity exists in the use of Sph by the two different 
metabolic routes. Moreover, we show that the two cell types had different 
kinetics of Cer consumption. Both types of Cer consumption, which convert Cer 
to SM and GlcCer were potentiated in SC02, and appear functional to avoid Cer 
accumulation in these cells. A further result of the metabolic experiments was 
that GSCs constitutively exhibit the property to efficiently release S1P in the 
extracellular microenvironment, in line with previous recent study (Riccitelli E, 
et al., 2013). The novel finding is that the proliferative properties of GSCs 
appeared as related to efficient and rapid release of newly produced S1P. Indeed 
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extracellular S1P level was up to 10-fold higher in SC02 than SC01, suggesting 
that the high extent of S1P release by SC02 cells reflects, and most probably 
participates, in their proliferation and stemness features. In spite representative 
of different GSC lines, the limited number of GSC lines here used and the 
heterogeneity of GMBs warrant further studies to confirm these findings. 
Overall, these metabolic experiments demonstrate that fast proliferating cells 
exhibit an increased flux through the pathway converting Sph to S1P, paralleled 
by an increase of Cer to complex sphingolipids, the most relevant changes being 
gain of extracellular S1P and loss of intracellular Sph and Cer. Since the balance 
between S1P and Cer/Sph levels is believed to provide a rheostat mechanism 
determinant for cell proliferation and fate (Spiegel & Merrill, 1996), our results 
suggest that altering this rheostat in favor of S1P provides SC02 an advantage in 
their proliferative and stemness qualities. In agreement, a decrease in total 
ceramides and an increase in S1P content with increasing glioma grade were 
reported (Abuhusain et al., 2013; Riboni et al., 2002). 
Further results here obtained underscore the relevance of the extracellular 
environment in affecting the extent of S1P export. The finding that S1P 
promotes stemness parameters in GSCs, might reside in its ability to promote 
either the expression of different stem markers or the proliferation of GSCs that 
are already expressing stem cell markers. In non-stem primary GBM cells, we 
observed that S1P did not induce stemness marker expression, thus suggesting 
that its effect resides in the selective expansion of GSCs. 
We observed that S1P treatment resulted in elevation of the CD133+ population 
of GSCs. It is worth noting that this subpopulation of GSCs was demonstrated to 
present a more malignant behaviour, and is able to maintain the GSC pool in the 
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tumor, also increasing its cellular heterogeneity (Lathia et al., 2011b; Zeppernick 
et al., 2008). Although at present the mechanisms of the stemness-promoting 
action of S1P are unknown, it appears reasonable that the S1P might induce the 
expansion of CD133+ GSCs, and/or their dedifferentiation to CD133+ GSCs. Of 
interest, besides CD133+ cells, S1P increased the CD15+ population too, and 
this population was reported to complement some part of CD133 function, as it 
survives better and proliferates faster than their negative counterpart (Zeppernick 
et al., 2008). We found that S1P also increased the number of cells expressing 
the hematopoietic/endothelial progenitor markers CD31+and CD34+. 
Intriguingly, CD31+ and CD34+ GSCs were found to co-express CD133+, and 
to be more proliferating than the negative counterpart (Christensen et al., 2011). 
Overall, these data suggest that fast-proliferating GSCs possess a high 
propensity for secreting S1P, and that autocrine S1P acts as microenvironmental 
signal to increase the GSC population and to enhance their stem cell properties. 
Besides emphasizing the importance of S1P as a proliferative factor, this study 
underscores S1P export as a crucial step in connecting GSCs with their niche, 
and suggests that S1P secretion by GSCs may also have the effect of targeting 
functions of nonstem niche cells in a paracrine manner. In line with this, S1P has 
been reported to favour propagation of non-stem cell types present in the GSC 
niche, such as astrocytes (Bassi et al., 2006), endothelial cells (Rosen et al., 
2005), and as confirmed in our study, in non-stem glioma cells, too (Van 
Brocklyn et al., 2002; Yoshida et al., 2010). Additionally, our results revealed 
that FTY720, when administrated in combination with the chemotherapeutic 
agent TMZ, sensibilized GSCs to chemotherapy enhancing autophagic death. As 
previously described by Estrada-Bernal and collaborators, FTY720 treatment of 
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brain tumor stem cells from GBM led to rapid inactivation of ERK MAP kinase, 
leading to apoptosis in combination with TMZ. In in vivo mouse model of GBM, 
FTY720 augmented the therapeutic effect of TMZ, increasing the survival rate 
(Estrada-Bernal A, et al., 2012). FTY720 received Food and Drug 
Administration approval for treatment of relapsing multiple sclerosis and, thus, 
has been shown to be well-tolerated in human patients and to enter the central 
nervous system. All in all, this research project showed significantly results 
regarding the involvement of sphingolipids in conferring resistance to GSCs.  
Hence, not only genetic and epigenetic modifications can play a key role in the 
progression, aggressiveness and recurrence of the disease, but also metabolic 
changes may adversely affect the development of this malignant tumor.  
These findings have provided a compelling rationale for involvement of S1P 
receptor antagonists, as a new approach to anticancer drug development. 
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